COMPOUNDS THAT INHIBIT INTERACTION BETWEEN SIGNAL-TRANSDUCING PROTEINS AND THE GLGF (PDZ/DHR) DOMAIN AND USES THEREOF

Abstract: This invention provides for a composition capable of inhibiting specific binding between a signal-transducing protein and a cytoplasmic protein. This invention also provides a method of identifying a compound capable of inhibiting specific binding between a signal-transducing protein and a cytoplasmic protein. This invention also provides a method of inhibiting the proliferation of cancer cells. This invention also provides a method of treating cancer with a composition in an amount effective to result in an amount in apoptosis of the cells. This invention also provides a method of inhibiting the proliferation of virally infected cells. This invention also provides for a method of treating a virally-infected subject with a composition in an amount effective to result in apoptosis of the cells. This invention also provides for pharmaceutical compositions.

Description: COMPOUNDS THAT INHIBIT INTERACTION BETWEEN SIGNAL-TRANSDUCING PROTEINS AND THE GLGF (PDZ/DHR) DOMAIN AND USES THEREOF The invention disclosed herein was made with Government support under Grant No. R01GM55147-01 from the National Institutes of Health of the United States Department of Health and Human Services. Accordingly, the U.S. Government has certain rights in this invention. BACKGROUND Throughout this application, various publications are referenced by author and date. Full citations for these publications may be found listed alphabetically at the end of the specification immediately preceding Sequence Listing and the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein. Fas (APO-1/CD95) and its ligand have been identified as important signal-mediators of apoptosis (Itoh, et al . 1991) The structural organization of Fas (APO-1/CD95) has suggested that it is a member of the tumor necrosis factor receptor superfamily, which also includes the p75 nerve growth factor receptor (NGFR) (Johnson, et al. 1986) , the T-cell-activation marker CD27 (Camerini, et al . 1991), the Hodgkin-lymphoma-associated antigen CD30 (Smith, et al . (1993), the human B cell antigen CD40 (Stamenkovic, et al . 1989), and T cell antigen OX40 (Mallett, et al . 1990). Genetic mutations of both Fas and its ligand have been associated with ly phoproliferative and autoimmune disorders in mice ( atanabe-Fukunaga, et al . 1992; Takahashi , et al . 1994). Furthermore, alterations of Fas expression level have been thought to lead to the induction of apoptosis in T-cells infected with human immunodeficiency virus (HIV) (Westendorp, et al. 1995) . Several Fas- interacting signal transducing molecules, such as Fas-associated phosphatase-1 (FAP-1) (Figure 1) (Sato, et al. 1995) FADD/MORTl/CAP-l/CAP-2 (Chinnaiyan, et al. 1995; Boldin, et al . 1995; Kischkel, et al . 1995) and RIP (Stanger, et al . 1995), have been identified using yeast two-hybrid and biochemical approaches. All but FAP-1 associate with the functional cell death domain of Fas and overexpression of FADD/M0RT1 or RIP induces apoptosis in cells transfected with these proteins . In contrast, FAP-1 is the only protein that associates with the negative regulatory domain (C-terminal 15 amino acids) (Ito, et al. 1993) of Fas and that inhibits Fas-induced apoptosis. FAP-1 (PTPN13) has several alternatively-spliced forms that are identical to PTP-BAS/hPTPlE/PTPLl, ( aekawa, et al. 1994; Banville, et al . 1994; Saras, et al . 1994) and contains a membrane-binding region similar to those found in the cytoskeleton-associated proteins, ezrin, (Gould et al . 1989) radixin (Funayama et al . 1991) moesin (Lankes, et al . 1991), neurofibromatosiε type II gene product (NFII) (Rouleau, et al . 1993), and protein 4.1 (Conboy, et al. 1991), as well as in the PTPases PTPH1 (Yang, et al. 1991), PTP-MEG (Gu, et al . 1991), and PTPD1 (Vogel, et al . 1993). FAP-1 intriguingly contains six GLGF (PDZ/DHR) repeats that are thought to mediate intra-and inter-molecular interactions among protein domains. The third GLGF repeat of FAP-1 was first identified as a domain showing the specific interaction with the C-terminus of Fas receptor (Sato, et al . 1995) . This suggests that the GLGF domain may play an important role in targeting proteins to the submembranous cytoskeleton and/or in regulating biochemical activity. GLGF repeats have been previously found in guanylate kinases, as well as in the rat post-synaptic density protein (PSD-95) (Cho, et al . 1992), which is a homolog of the Drosophila tumor suppressor protein, lethal- (1) -disc-large-1 [dlg- 1] (Woods, et al 1991; Kita ura, et al . 1994). These repeats may mediate homo- and hetero-dimerization, which could potentially influence PTPase activity, binding to Fas, and/or interactions of FAP-1 with other signal transduction proteins. Recently, it has also been reported that the different PDZ domains of proteins interact with the C-terminus of ion channels and other proteins (Figure 1) (TABLE 1) (Kornau, et al . 1995; Kim, et al. 1995; Matsumine, et al . 1996). TABLE 1. Proteins that interact with PDZ domains. Protein C-terminal Associated Reference sequence protein Fas (APO-1/CD95) SLV FAP-1 2 NMDA receptor SDV PSD95 3 NR2 subunit Shaker-type K+ TDV PSD95 & DLG 4 channel APC TEV DLG 5 SUMMARY OF THE INVENTION This invention provides a composition capable of inhibiting specific binding between a signal-transducing protein and a cytoplasmic protein containing the amino acid sequence (G/S/A/E) -L-G- (F/I/L) (Sequence I.D. No.: 1) . Further, the cytoplasmic protein may contain the amino acid sequence (K/R/Q) -X n - (G/S/A/E) -L-G- (F/I/L) (Sequence I.D. No.: 2), wherein X represents any amino acid which is selected from the group comprising the twenty naturally occurring amino acids and n represents at least 2, but not more than 4. In a preferred embodiment, the amino acid sequence is SLGI (Sequence I.D. No.: 3) . Further, the invention provides for a composition when the signal -transducing protein has at its carboxyl terminus the amino acid sequence (S/T) -X- (V/I/L) (Sequence I.D. No.: 4), wherein each - represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, each slash within such parentheses separating the alternative amino acids, and the X represents any amino acid which is selected from the group comprising the twenty naturally occurring amino acids. This invention also provides for a method of identifying a compound capable of inhibiting specific binding between a signal-transducing protein and a cytoplasmic protein containing the amino acid sequence (G/S/A/E) -L-G- (F/I/L) . Further this invention provides for a method of identifying a compound capable of inhibiting specific binding between a signal-transducing protein having at its carboxyl terminus the amino acid sequence (S/T) -X- (V/L/I) and a cytoplasmic protein. This invention also provides for a method inhibiting the proliferation of cancer cells, specifically, where the cancer cells are derived from organs comprising the colon, liver, breast, ovary, testis, lung, stomach, spleen, kidney, prostate, uterus, skin, head, thymus and neck, or the cells are derived from either T-cells or B- cells . This invention also provides for a method of treating cancer in a subject in an amount of the composition of effective to result in apoptosis of the cells, specifically, where the cancer cells are derived from organs comprising the thymus, colon, liver, breast, ovary, testis, lung, stomach, spleen, kidney, prostate, uterus, skin, head and neck, or the cells are derived from either T-cells or B-cells. This invention also provides for a method of inhibiting the proliferation of virally infected cells, specifically wherein the virally infected cells are infected with the Hepatitis B virus, Epstein-Barr virus, influenza virus, Papilloma virus, Adenovirus, Human T-cell lymphtropic virus, type 1 or HIV. This invention also provides a pharmaceutical composition comprising compositions capable of inhibiting specific binding between a signal-transducing protein and a cytoplasmic protein. This invention also provides a pharmaceutical composition comprising compounds identified to be capable of inhibiting specific binding between a signal -transducing protein and a cytoplasmic protein. BRIEF DESCRIPTION OF THE FIGURES Figure 1. Diagram of Fas-associated phosphatase-1 protein, showing the six GLGF (PDZ/DHR) domain repeats; comparison of similar membrane binding sites with other proteins and proteins that contain GLGF (PDZ/DHR) repeats. Figures 2A, 2B, 2C and 2D. Mapping of the minimal region of the C-terminal of Fas required for the binding to FAP-1. Numbers at right show each independent clone (Figures 2C and 2D) . 2A. Strategy for screening of a random peptide library by the yeast two-hybrid system. 2-3. Alignment of the C- terminal 15 amino acids of Fas between human (Sequence I.D. No. : 5) , rat (Sequence I.D. No . : 6) , and mouse (Sequence I.D. No. : 7) . 2C. The results of screening a semi-random peptide library. Top row indicates the amino acids which were fixed based on the homology between human and rat. Dash lines show unchanged amino acids. 2D. The results of screening a random peptide library (Sequence I.D. No . : 8, Sequence I.D. No. : 9, Sequence I.D. No. 10, Sequence I.D. No. 11, Sequence I.D. No. 12, Sequence I.D. No. 13, Sequence I.D. No. 14, Sequence I.D. No. 15, Sequence I.D. No. 16, Sequence I.D. No. 17, respectively) . Figures 3A, 3B and 3C. Inhibition assay of Fas/FAP-1 binding in vitro. 3A. Inhibition assay of Fas/FAP-1 binding using the C-terminal 15 amino acids of Fas. GST-Fas fusion protein (191-355) was used for in vi tro binding assay (lane 1, 3-10) . GST-Fas fusion protein (191-320) (lane 2) and 1 mM human PAMP (N-terminal 20 amino acids of proadrenomedullin, M.W. 2460.9) (lane 3) were used as negative controls. The concentrations of the C-terminal 15 amino acids added were 1 (lane 4) , 3 (lane 5) , 10 (lane 6) , 30 (lane 7), 100 (lane 8), 300 (lane 9), and 1000 μM (lane 10) . 3B. Inhibition assay of Fas/FAP-1 binding using the truncated peptides corresponding to the C-terminal 15 amino acids of Fas. All synthetic peptides were acetylated for this inhibition assay (Sequence I.D. No.: 4, Sequence I.D. No.: 18, Sequence I.D. No.: 19, Sequence I.D. No.: 20, Sequence I.D. No.: 21, Sequence I.D. No.: 22, Sequence I.D. No.: 23, respectively) . 3C. Inhibitory effect of Fas/FAP-1 binding using the scanned tripeptides. Figures 4A, 4B, 4C and 4D. 4A. Interaction of the C-terminal 3 amino acids of Fas with FAP-1 in yeast. 4B. Interaction of the C-terminal 3 amino acids of Fas with FAP-1 in vitro. 4C. Immuno-precipitation of native Fas with GST-FAP-1. 4D. Inhibition of Fas/FAP-1 binding with Ac-SLV or Ac- SLY. Figures 5A, 5B, 5C, 5D, 5E and 5F. Microinjection of Ac-SLV into the DLD-1 cell line. Triangles identify the cells both that were could be microinjected with Ac-SLV and that showed condensed chromatin identified. On the other hand, only one cell of the area appeared apoptotic when microinjected with Ac-SLY. 5A. Representative examples of the cells microinjected with Ac-SLV in the presence of 500 ng/ml CH11 are shown in phase contrast . 5B . Representative examples of the cells microinjected with AC-SLY in the presence of 500 ng/ml CH11 are shown in phase contrast. 5C. Representative examples of the cells microinjected with Ac-SLV in the presence of 500 ng/ml CH11 are shown stained with FITC. 5D. Representative examples of the cells microinjected with AC-SLY in the presence of 500 ng/ml CH11 are shown stained with FITC. 5E . Representative examples of the cells microinjected with Ac-SLV in the presence of 500 ng/ml CH11 are shown with fluorescent DNA staining with Hoechst 33342. 5F. Representative examples of the cells microinjected with AC-SLY in the presence of 500 ng/ml CH11 are shown in fluorescent DNA staining with Hoechst 33342. Figure 6. Quantitation of apoptosis in microinjected DLD-1 cells. Figures 7A, 7B, 7C, 7D, 7E, 7F, 7G, and 7H. 7A. Amino acid sequence of human nerve growth factor receptor (Sequence I.D. No.: 24). 7B . Amino acid sequence of human CD4 receptor (Sequence I.D. No. 25) . 7C. The interaction of Fas-associated phosphatase-1 to the C-terminal of nerve growth factor receptor (NGFR) (p75) . 7D. Amino acid sequence of human colorectal mutant cancer protein (Sequence I.D. No. : 26) . 7E . Amino acid sequence of protein kinase C, alpha type. 7F. Amino acid sequence of serotonin 2A receptor (Sequence I.D. No.: 27). 7G. Amino acid sequence of serotonin 2B receptor (Sequence I.D. No.: 28). 7H. Amino acid sequence of adenomatosis polyposis coli protein (Sequence I.D. No.: 29). Figure 8. Representation of the structural characteristics of p75 NGFR (low-affinity nerve growth factor receptor) . Figure 9. Comparison of the C-terminal ends of Fas and p75 NGFR. Figure 10. In vitro interaction of 35 S-labeled FAP-1 with various receptors expressed as GST fusion proteins . The indicated GST fusion proteins immobilized on glutathione- Sepharose beads were incubated with in vitro translated, 3b S- labeled FAP-1 protein. After the beads were washed, retained FAP-1 protein was analyzed by SDS-PAGE and autoradiography. Figures 11A and 11B. In vitro interaction 35 S-labeled FAP-1 with GST-p75 deletion mutants. 11A. Schematic representation of the GST fusion proteins containing the cytoplasmic domains of p75 and p75 deletion mutants. Binding of FAP- 1 to the GST fusion proteins with various p75 deletion mutants is depicted at the right and is based on data from (11B) . 11B. Interaction of in vitro translated, 35 S- labeled FAP-1 protein with various GST fusion proteins immobilized on glutathione-Sepharose beads. After the beads were washed, retained FAP-1 protein was analyzed by SDS-PAGE and autoradiography . Figure 12. The association between LexA-C-terminal cytoplasmic region of p75NGFR and VP16-FAP-1. The indicated yeast strains were constructed by transformation and the growth of colonies was tested. +/- indicates the growth of colonies on his " plate. DETAILED DESCRIPTION OF THE INVENTION As used herein, amino acid residues are abbreviated as follows: A, Ala; C, Cys ; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, He; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gin; R, Arg; S, Ser,- T, Thr; V, Val; W, Trp; and Y, Tyr. In order to facilitate an understanding of the material which follows, certain frequently occurring methods and/or terms are best described in Sambrook, et al . , 1989. The present invention provides for a composition capable of inhibiting specific binding between a signal - transducing protein and a cytoplasmic protein containing the amino acid sequence (G/S/A/E) -L-G- (F/I/L) , wherein each - represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, and each slash within such parentheses separating the alternative amino acids. Further, the cytoplasmic protein may contain the amino acid sequence (K/R/Q) -X n - (G/S/A/E) -L-G- (F/I/L) , wherein X represents any amino acid which is selected from the group comprising the twenty naturally occurring amino acids and n represents at least 2, but not more than 4. Specifically, in a preferred embodiment, the cytoplasmic protein contains the amino acid sequence SLGI . The amino acid sequence (K/R/Q) -X n - (G/S/A/E) -L-G- (F/I/L) is also well-known in the art as "GLGF (PDZ/DHR) amino acid domain." As used herein, "GLGF (PDZ/DHR) amino acid domain" means the amino acid sequence (K/R/Q) -X n - (G/S/A/E) -L-G- (F/I/L) . In a preferred embodiment , the signal -transducing protein has at its carboxyl terminus the amino acid sequence (S/T) -X- (V/I/L) , wherein each - represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, each slash within such parentheses separating the alternative amino acids, and the X represents any amino acid which is selected from the group comprising the twenty naturally occurring amino acids . The compositions of the subject invention may be, but not limited to, antibodies, inorganic compounds, organic compounds, peptides, peptidomimetic compounds, polypeptides or proteins, fragments or derivatives which share some or all properties, e.g. fusion proteins. The composition may be naturally occurring and obtained by purification, or may be non-naturally occurring and obtained by synthesis. Specifically, the composition may be a peptide containing the sequence (S/T) -X- (V/I/L) -COOH, wherein each represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, each slash within such parentheses separating the alternative amino acids, the X represents any amino acid which is selected from the group comprising the twenty naturally occurring amino acids. In preferred embodiments, the peptide contains one of the following sequences: DSENSNFRNEIQSLV, RNEIQSLV, NEIQSLV, EIQSLV, IQSLV, QSLV, SLV, IPPDSEDGNEEQSLV, DSEMYNFRSQLASW, IDLASEFLFLSNSFL, PPTCSQANSGRISTL, SDSN NMNELSEV, QNFRTYIVSFV, RETIESTV, RGFISSLV, TIQSVI, ESLV. A further preferred embodiment would be an organic compound which has the sequence Ac- SLV-COOH, wherein the Ac represents an acetyl and each - represents a peptide bond. An example of the subject invention is provided infra. Acetylated peptides may be automatically synthesized on an Advanced Che Tech ACT357 using previously published procedures by analogy. Wang resin was used for each run and N^-Fmoc protection was used for all amino acids, and then 20% piperidine/DMF and coupling was completed using DIC/HOBt and subsequently HBTU/DIEA. After the last amino acid was coupled, the growing peptide on the resin was acetylated with Ac 2 0/DMF . The acetylated peptide was purified by HPLC and characterized by FAB-MS and * Η-NMR. Further, one skilled in the art would know how to construct derivatives of the above-described synthetic peptides coupled to non-acetyl groups, such as amines. This invention also provides for a composition capable of inhibiting specific binding between a signal-transducing protein having at its carboxyl terminus the amino acid sequence (S/T) -X- (V/I/L) , wherein each - represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, each slash within such parentheses separating the alternative amino acids, the X represents any amino acid which is selected from the group comprising the twenty naturally occurring amino acids, and a cytoplasmic protein. The compositions of the subject invention includes antibodies, inorganic compounds, organic compounds, peptides, peptidomimetic compounds, polypeptides or proteins, fragments or derivatives which share some or all properties, e.g. fusion proteins. This invention also provides a method of identifying a compound capable of inhibiting specific binding between a signal-transducing protein and a cytoplasmic protein containing the amino acid sequence (G/S/A/E) -L-G- (F/I/L) , wherein each - represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, each slash within such parentheses separating the alternative amino acids, which comprises (a) contacting the cytoplasmic protein bound to the signal-transducing protein with a plurality of compounds under conditions permitting binding between a known compound previously shown to be able to displace the signal -transducing protein bound to the cytoplasmic protein and the bound cytoplasmic protein to form a complex; and (b) detecting the displaced signal- transducing protein or the complex formed in step (a) wherein the displacement indicates that the compound is capable of inhibiting specific binding between the signal -transducing protein and the cytoplasmic protein. The inhibition of the specific binding between the signal-transducing protein and the cytoplasmic protein may affect the transcription activity of a reporter gene. Further, in step (b) , the displaced cytoplasmic protein or the complex is detected by comparing the transcription activity of a reporter gene before and after the contacting with the compound in step (a) , where a change of the activity indicates that the specific binding between the signal-transducing protein and the cytoplasmic protein is inhibited and the signal - transducing protein is displaced. As used herein, the "transcription activity of a reporter gene" means that the expression level of the reporter gene will be altered from the level observed when the signal-transducing protein and the cytoplasmic protein are bound. One can also identify the compound by detecting other biological functions dependent on the binding between the signal-transducing protein and the cytoplasmic protein. Examples of reporter genes are numerous and well-known in the art, including, but not limited to, histidine resistant genes, ampicillin resistant genes, jβ-galactosidase gene. Further the cytoplasmic protein may be bound to a solid support. Also the compound may be bound to a solid support and comprises an antibody, an inorganic compound, an organic compound, a peptide, a peptidomimetic compound, a polypeptide or a protein. An example of the method is provided infra . One can identify a compound capable of inhibiting specific binding between the signal -transducing protein and the cytoplasmic protein using direct methods of detection such as immuno-precipitation of the cytoplasmic protein and the compound bound to a detectable marker. Further, one could use indirect methods of detection that would detect the increase or decrease in levels of gene expression. As discussed infra, one could construct synthetic peptides fused to a LexA DNA binding domain. These constructs would be transformed into the L40-strain with an appropriate cell line having an appropriate reporter gene. One could then detect whether inhibition had occurred by detecting the levels of expression of the reporter gene. In order to detect the expression levels of the reporter gene, one skilled in the art could employ a variety of well-known methods, e.g. two-hybrid systems in yeast, mammals or other cells. Further, the contacting of step (a) may be in vitro, in vivo, and specifically in an appropriate cell, e.g. yeast cell or mammalian cell. Examples of mammalian cells include, but not limited to, the mouse fibroblast cell NIH 3T3, CHO cells, HeLa cells, Ltk " cells, Cos cells, etc. Other suitable cells include, but are not limited to, prokaryotic or eukaryotic cells, e.g. bacterial cells (including gram positive cells), fungal cells, insect cells, and other animals cells. Further, the signal-transducing protein may be a cell surface receptor, signal transducer protein, or a tumor suppressor protein. Specifically, the cell surface protein is the Fas receptor and may be expressed in cells derived from organs including, but not limited to, thymus, liver, kidney, colon, ovary, breast, testis, spleen, lung, stomach, prostate, uterus, skin, head, and neck, or expressed in cells comprising T-cells and B- cells. In a preferred embodiment, the T-cells are Jurkat T-cells. Further, the cell-surface receptor may be a CD4 receptor, p75 receptor, serotonin 2A receptor, or serotonin 2B receptor. Further, the signal transducer protein may be Protein Kinase-C-α-type. Further, the tumor suppressor protein may be a adenomatosis polyposis coli tumor suppressor protein or colorectal mutant cancer protein. Further, the cytoplasmic protein contains the amino acid sequence SLGI , specifically Fas-associated phosphatase-1. This invention also provides a method of identifying a compound capable of inhibiting specific binding between a signal-transducing protein having at its carboxyl terminus the amino acid sequence (S/T) -X- (V/I/L) , wherein each - represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, each slash within such parentheses separating the alternative amino acids, the X represents any amino acid which is selected from the group comprising the twenty naturally occurring amino acids, and a cytoplasmic protein which comprises (a) contacting the signal- transducing protein bound to the cytoplasmic protein with a plurality of compounds under conditions permitting binding between a known compound previously shown to be able to displace the cytoplasmic protein bound to the signal-transducing protein and bound signal -transducing protein to form a complex; and (b) detecting the displaced cytoplasmic protein or the complex of step (a) , wherein the displacement indicates that the compound is capable of inhibiting specific binding between the signal-transducing protein and the cytoplasmic protein. The inhibition of the specific binding between the signal-transducing protein and the cytoplasmic protein affects the transcription activity of a reporter gene. Further, in step (b) , the displaced signal-transducing protein or the complex is detected by comparing the transcription activity of a reporter gene before and after the contacting with the compound in step (a) , where a change of the activity indicates that the specific binding between the signal-transducing protein and the cytoplasmic protein is inhibited and the cytoplasmic protein is displaced. Further, in step (b) , the displaced cytoplasmic protein or the complex is detected by comparing the transcription activity of a reporter gene before and after the contacting with the compound in step (a) , where a change of the activity indicates that the specific binding between the signal-transducing protein and the cytoplasmic protein is inhibited and the signal- transducing protein is displaced. As used herein, the "transcription activity of a reporter gene" means that the expression level of the reporter gene will be altered from the level observed when the signal-transducing protein and the cytoplasmic protein are bound. One can also identify the compound by detecting other biological functions dependent on the binding between the signal -transducing protein and the cytoplasmic protein. Examples of reporter genes are numerous and well-known in the art, including, but not limited to, histidine resistant genes, ampicillin resistant genes, β-galactosidase gene. Further, the cytoplasmic protein may be bound to a solid support or the compound may be bound to a solid support, comprises an antibody, an inorganic compound, an organic compound, a peptide, a peptidomimetic compound, a polypeptide or a protein. An example of the method is provided infra . One could identify a compound capable of inhibiting specific binding between the signal -transducing protein and the cytoplasmic protein using direct 'methods of detection such as immuno-precipitation of the cytoplasmic protein and the compound bound with a detectable marker. Further, one could use indirect methods of detection that would detect the increase or decrease in levels of gene expression. As discussed infra, one could construct synthetic peptides fused to a LexA DNA binding domain. These constructs would be transformed into L40-strain with an appropriate cell line having a reporter gene. One could then detect whether inhibition had occurred by detecting the levels of the reporter gene. Different methods are also well known in the art, such as employing a yeast two-hybrid system to detect the expression of a reporter gene. Further the contacting of step (a) can be in vitro or in vivo, specifically in a yeast cell or a mammalian cell . Examples of mammalian cells include, but not limited to, the mouse fibroblast cell NIH 3T3 , CHO cells, HeLa cells, Ltk " cells, Cos cells, etc. Other suitable cells include, but are not limited to, prokaryotic or eukaryotic cells, e.g. bacterial cells ( including gram positive cells) , fungal cells, insect cells, and other animals cells. Further, the signal-transducing protein is a cell surface receptor, signal transducer protein, or a tumor suppressor protein. Specifically, the cell surface protein is the Fas receptor and is expressed in cells derived from organs comprising thymus, liver, kidney, colon, ovary, breast, testis, spleen, stomach, prostate, uterus, skin, head and neck, or expressed in cells comprising T-cells and B-cells. In a preferred embodiment, the T-cells are Jurkat T-cells. Further, the cell-surface receptor may be a CD4 receptor, p75 receptor, serotonin 2A receptor, or serotonin 2B receptor. Further, the signal transducer protein may be Protein Kinase-C-α-type . Further, the tumor suppressor protein may be a adenomatosis polyposis coli tumor suppressor protein or colorectal mutant cancer protein. Further, the cytoplasmic protein contains the amino acid sequence SLGI, specifically Fas-associated phosphatase- 1. This invention also provides a method of inhibiting the proliferation of cancer cells comprising the above- described composition, specifically, wherein the cancer cells are derived from organs including, but not limited to, thymus, liver, kidney, colon, ovary, breast, testis, spleen, stomach, prostate, uterus, skin, head and neck, or wherein the cancer cells are derived from cells comprising T-cells and B-cells. This invention also provides a method of inhibiting the proliferation of cancer cells comprising the compound identified by the above-described method, wherein the cancer cells are derived from organs including, but not limited to, thymus, liver, kidney, colon, ovary, breast, testis, spleen, stomach, prostate, uterus, skin, head and neck, or wherein the cancer cells are derived from cells comprising T-cells and B-cells. The invention also provides a method of treating cancer in a subject which comprises introducing to the subject's cancerous cells an amount of the above-described composition effective to result in apoptosis of the cells, wherein the cancer cells are derived from organs including, but not limited to, thymus, liver, kidney, colon, ovary, breast, testis, spleen, stomach, prostate, uterus, skin, head and neck, or wherein the cancer cells are derived from cells comprising T-cells and B-cells. As used herein "apoptosis" means programmed cell death of the cell. The mechanisms and effects of programmed cell death differs from cell lysis. Some observable effects of apoptosis are: DNA fragmentation and disintegration into small membrane-bound fragments called apoptotic bodies. Means of detecting whether the composition has been effective to result in apoptosis of the cells are well- known in the art . One means is by assessing the morphological change of chromatin using either phase contrast or fluorescence microscopy. The invention also provides for a method of inhibiting the proliferation of virally infected cells comprising the above-described composition or the compound identified by the above-described, wherein the virally infected cells comprise Hepatitis B virus, Epstein-Barr virus, influenza virus, Papilloma virus, Adeno virus, Human T-cell lymphtropic virus, type 1 or HIV. The invention also provides a method of treating a virally- infected subject which comprises introducing to the subject's virally- infected cells the above-described composition effective to result in apoptosis of the cells or the compound identified by the above-described method of claim 27 effective to result in apoptosis of the cells, wherein the virally infected cells comprise the Hepatitis B virus, Epstein-Barr virus, influenza virus, Papilloma virus, Adeno virus, Human T-cell lymphtropic virus, type 1 or HIV. Means of detecting whether the composition has been effective to result in apoptosis of the cells are well- known in the art . One means is by assessing the morphological change of chro atin using either phase contrast or fluorescence microscopy. This invention also provides for a pharmaceutical composition comprising the above-described composition of in an effective amount and a pharmaceutically acceptable carrier . This invention also provides for a pharmaceutical composition comprising the compound identified by the above-described method of in an effective amount and a pharmaceutically acceptable carrier. This invention further provides a composition capable of specifically binding a signal-transducing protein having at its carboxyl terminus the amino acid sequence (S/T) -X- (V/L/I) , wherein each - represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, each slash within such parentheses separating the alternative amino acids, and the X represents any amino acid which is selected from the group comprising the twenty naturally occurring amino acids. The composition may contain the amino acid sequence (G/S/A/E) -L-G- (F/I/L) , wherein each - represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, and each slash within such parentheses separating the alternative amino acids. In a preferred embodiment, the composition contains the amino acid sequence (K/R/Q) -X n - (G/S/A/E) -L-G- (F/I/L) . wherein X represents any amino acid which is selected from the group comprising the twenty naturally occurring amino acids and n represents at least 2, but not more than 4. In another preferred embodiment, the composition contains the amino acid sequence SLGI . This invention further provides a method for identifying compounds capable of binding to a signal-transducing protein having at its carboxyl terminus the amino acid sequence (S/T) -X- (V/L/I) , wherein each - represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, each slash within such parentheses separating the alternative amino acids, the X represents any amino acid which is selected from the group comprising the twenty naturally occurring amino acids, which comprises (a) contacting the signal- transducing protein with a plurality of compounds under conditions permitting binding between a known compound previously shown to be able to bind to the signal- transducing protein to form a complex; and (b) detecting the complex formed in step (a) so as to identify a compound capable of binding to the signal-transducing protein. Specifically, the identified compound contains the amino acid sequence (G/S/A/E) -L-G- (F/I/L) . In a further preferred embodiment, the identified compound contains the amino acid sequence SLGI. Further, in the above-described method, the signal- transducing protein may be bound to a solid support. Also, the compound may be bound to a solid support, and may comprise an antibody, an inorganic compound, an organic compound, a peptide, a peptidomimetic compound, a polypeptide or a protein. Further, the signal-transducing protein may be a cell- surface receptor or a signal transducer. Specifically, the signal -transducing protein may be the Fas receptor, CD4 receptor, p75 receptor, serotonin 2A receptor, serotonin 2B receptor, or protein kinase-C-α-type . This invention also provides a method of restoring negative regulation of apoptosis in a cell comprising the above-described composition or a compound identified by the above-described method. As used herein "restoring negative regulation of apoptosis" means enabling the cell from proceeding onto programmed cell death. For example, cells that have functional Fas receptors and Fas-associated phosphatase 1 do not proceed onto programmed cell death or apoptosis due to the negative regulation of Fas by the phosphatase. However, if Fas- associated phosphatase 1 is unable to bind to the carboxyl terminus of the Fas receptor ( (S/T) -X- (V/L/I ) region) , e.g. mutation or deletion of at least one of the amino acids in the amino acid sequence (G/S/A/E) -L-G- (F/I/L), the cell will proceed to apoptosis. By introducing a compound capable of binding to the carboxyl terminus of the Fas receptor, one could mimic the effects of a functional phosphatase and thus restore the negative regulation of apoptosis. This invention also provides a method of preventing apoptosis in a cell comprising the above-described composition or a compound identified by the above- described method. This invention also provides a means of treating pathogenic conditions caused by apoptosis of relevant cells comprising the above-described composition or the compound identified by the above-described method. This invention is illustrated in the Experimental Details section which follows. These sections are set forth to aid in an understanding of the invention but are not intended to, and should not be construed to, limit in any way the invention as set forth in the claims which follow thereafter. FIRST SERIES OF EXPERIMENTS Experimental Details Methods and Materials 1. Screening a semi-random and random peptide library. To create numerous mutations in a restricted DNA sequence, PCR utagenesis with degenerate oligonucleotides was employed according to a protocol described elsewhere (Hill, et al . 1987). Based on the homology between human and rat, two palindromic sequences were designed for construction of semi-random library. T h e two pr imers used we re 5 ' - CGGAATTCN N N N AACAGCNNN NNN NAATGAA πrCAAAGTCTGNN NTGAGGATCCTCA-3 ' (Seq. I.D. No.: 30) and 5 ' -CGGAATTCGACTCAGAANNNNNN-^CTTCAGANNyfNNNATCNNNl^SJNNNNGT CTGAGGATCCTCA-3 ' (Seq. I.D. No.: 31). Briefly, the two primers (each 200 pmol), purified by HPLC, were annealed at 70 °C for 5 minutes and cooled at 23 °C for 60 minutes. A Klenow fragment (5 U) was used for filling in with a dNTP mix (final concentration, 1 mM per each dNTP) at 23°C for 60 minutes. The reaction was stopped with 1 μl of 0.5 M EDTA and the DNA was purified with ethanol precipitation. The resulting double-stranded DNA was digested with EcoRI and BamHI and re-purified by electrophoresis on non-denaturing polyacrylamide gels. The double-strand oligonucleotides were then ligated into the EcoRI -BamHI sites of the pBTM116 plasmid. The ligation mixtures were electroporated into the E. coli XLl-Blue MRF' (Stratagene) for the plasmid library. The large scale transformation was carried out as previously reported. The plasmid library was transformed into L40-strain cells (MATa , trpl , leu2 , his3 , ade2 , LYS2 : (lexAop) 4 -HIS3 , URA3 : : (lexAopf -lacZ) carrying the plasmid pVP16-31 containing a FAP-1 cDNA (Sato, et al . 1995) . Clones that formed on histidine-deficient medium (His + ) were transferred to plates containing 40 μg/ml X-gal to test for a blue reaction product (β-gal + ) in plate and filter assays. The clones selected by His' and β-gal + assay were tested for further analysis. The p a l i n d r o m i c o l i g o n u c l e o t i d e , 5' -CGGAATTC- (NNN) ,.,--TGAGGATCCTCA-3 ' (Seq. I.D. No. 32), was used for the construction of the random peptide library. Synthesis of peptides Peptides were automatically synthesized on an Advanced ChemTech ACT357 by analogy to published procedures (Schnorrenberg and Gerhardt , 1989). Wang resin (0.2-0.3 mmole scale) was used for each run and N a -Fmoc protection was employed for all amino acids. Deprotection was achieved by treatment with 20% piperidine/DMF and coupling was completed using DIC/HOBt and subsequent HBTU/DIEA. After the last amino acid was coupled, the growing peptide on the resin was acetylated with Ac 2 0/DMF . The peptide was cleaved from the resin with concomitant removal of all protecting groups by treating with TFA. The acetylated peptide was purified by HPLC and characterized by FAB-MS and -NMR. 3. Inhibition asssay of Fas/FAP-1 binding using the C- terminal 15 amino acids of Fas. HFAP-10 cDNA (Sato, et al . 1995) subcloned into the Bluescript vector pSK-II (Stratagene) was in vitro-translated from an internal methionine codon in the presence of 35 S-L-methionine using a coupled in vitro transcription/translation system (Promega, TNT lysate) and T7 RNA polymerase . The resulting 35 S-labeled protein was incubated with GST-Fas fusion proteins that had been immobilized on GST-Sepharose 4B affinity beads (Pharmacia) in a buffer containing 150 mM NaCl , 50 M Tris [pH 8.0], 5 mM DTT, 2 mM EDTA, 0.1 % NP-40, 1 mM PMSF, 50 μg/ml leupeptin, 1 mM Benzamidine, and 7 μg/ml pepstatin for 16 hours at 4 * C. After washing vigorously 4 times in the same buffer, associated proteins were recovered with the glutathione-Sepharose beads by centrifugation, eluted into boiling Laemmli buffer, and analyzed by SDS-PAGE and fluorography . 4. Inhibition assay of terminal 15 amino acids of Fas and inhibitory effect of Fas/FAP-1 binding using diverse tripeptides. In vitro-translated [ 35 S] HFAP-1 was purified with a NAP- 5 column (Pharmacia) and incubated with 3 μM of GST-fusion proteins for 16 hours at 4 * C. After washing 4 times in the binding buffer, radioactivity incorporation was determined in a b counter. The percentage of binding inhibition was calculated as follows: percent inhibition = [radioactivity incorporation using GST-Fas (191-335) with peptides - radioactivity incorporation using GST-Fas (191-320) with peptides] / [radioactivity incorporation using GST-Fas (191-335) without peptides - radioactivity incorporation using GST-Fas (191-320) without peptides] . n=3. 5. Interaction of the C-terminal 3 amino acids of Fas with FAP-1 in yeast and in vitro. The bait plasmids, pBTM116 (LexA) -SLV, -PLV, -SLY, and -SLA, were constructed and transformed into L40-strain with pVP16-FAP-l or -ras. Six independent clones from each transformants were picked up for the analysis of growth on histidine-deficient medium. GST-Fas, -SLV, and PLV were purified with GST-Sepharose 4B affinity beads (Pharmacia) . The methods for in vitro binding are described above . 6. Immuno-precipitation of native Fas with GST-FAP-1 and inhibition of Fas/FAP-1 binding with Ac-SLV. GST-fusion proteins with or without FAP-1 were incubated with cell extracts from Jurkat T-cells expressing Fas. The bound Fas was detected by Western analysis using anti-Fas monoclonal antibody (F22120, Transduction Laboratories) . The tripeptides, Ac-SLV and Ac-SLY were used for the inhibition assay of Fas/FAP-1 binding. 7. Microinjection of Ac-SLV into the DLD-1 cell line. DLD-1 human colon cancer cells were cultured in RPMI 1640 medium containing 10% FCS . For microinjection, cells were plated on CELLocate (Eppendorf) at 1 X 10 5 cells/2 ml in a 35 mm plastic culture dish and grown for 1 day. Just before microinjection, Fas monoclonal antibodies CH11 (MBL International) was added at the concentration of 500 ng/ml. All microinjection experiments were performed using an automatic microinjection system (Eppendorf transjector 5246, micro-manipulator 5171 and Femtotips) (Pantel, et al . 1995) . Synthetic tripeptides were suspended in 0.1% (w/v) FITC-Dextran (Sigma) /K-PBS at the concentration of 100 mM. The samples were microinjected into the cytoplasmic region of DLD-1 cells. Sixteen to 20 hours postinjection, the cells were washed with PBS and stained with 10 μg/ml Hoechst 33342 in PBS. After incubation at 37°C for 30 minutes, the cells were photographed and the cells showing condensed chromatin were counted as apoptotic. 8. Quantitation of apoptosis in microinjected DLD-1 cells . For each experiment, 25-100 cells were microinjected. Apoptosis of microinjected cells was determined by assessing morphological changes of chromatin using phase contrast and fluorescence microscopy (Wang, et al . , 1995; McGahon, et al . , 1995). The data are means +/- S.D. for two or three independent determinations. Discussion In order to identify the minimal peptide stretch in the C-terminal region of the Fas receptor necessary for FAP-1 binding, an in vi tro inhibition assay of Fas/FAP-1 binding was used using a series of synthetic peptides as well as yeast two-hybrid system peptide libraries (Figure 2A) . First, semi-random libraries (based on the homology between human and rat Fas) (Figures 2B and 2C) of 15 amino acids fused to a LexA DNA binding domain were constructed and co-transformed into yeast strain L40 with pVP16-31 (Sato, et al . 1995) that was originally isolated as FAP-l. After the selection of 200 His + colonies from an initial screen of 5.0 X 10 6 (Johnson, et al . 1986) transformants, 100 colonies that were β-galactosidase positive were picked for further analysis. Sequence analysis of the library plasmids encoding the C-terminal 15 amino acids revealed that all of the C-termini were either valine, leucine or isoleucine residues. Second, a random library of 4-15 amino acids fused to a LexA DNA binding domain was constructed and screened according to this strategy (Figure 2D) . Surprisingly, all of the third amino acid residues from the C-termini were serine, and the results of C-terminal amino acid analyses were identical to the screening of the semi-random cDNA libraries. No other significant amino acid sequences were found in these library screenings, suggesting that the motifs of the last three amino acids (tS-X-V/L/I) are very important for the association with the third PDZ domain of FAP-l and play a crucial role in protein-protein interaction as well as for the regulation of Fas-induced apoptosis. To further confirm whether the last three amino acids are necessary and sufficient for Fas/FAP-1 binding, plasmids of the LexA-SLV, -PLV, -PLY, -SLY, and -SLA fusion proteins were constructed and co-transformed into yeast with pVP16-FAP-l. The results showed that only LexA-SLV associated with FAP-l, whereas LexA-PLV, -PLY, -SLY, and -SLA did not (Figure 4A) . In vitro binding studies using various GST-tripeptide fusions and in vi tro-translated FAP-l were consistent with these results (Figure 4B) . In addition to yeast two-hybrid approaches, in vitro inhibition assay of Fas/FAP-1 binding was also used. First, a synthetic peptide of the C-terminal 15 amino acids was tested whether it could inhibit the binding of Fas and FAP-l in vi tro (Figure 3A) . The binding of in vitro-translated FAP-l to GST-Fas was dramatically reduced and dependent on the concentration of the synthetic 15 amino acids of Fas. In contrast with these results, human PAMP peptide (Kitamura, et al . 1994) as a negative control had no effect on Fas/FAP-1 binding activity under the same biochemical conditions. Second, the effect of truncated C-terminal synthetic peptides of Fas on Fas/FAP-1 binding in vi tro was examined. As shown in Figure 3B, only the three C-terminal amino acids (Ac-SLV) were sufficient to obtain the same level of inhibitory effect on the binding of FAP-l to Fas as achieved with the 4-15 synthetic peptides. Furthermore, Fas/FAP-1 binding was extensively investigated using the scanned tripeptides to determine the critical amino acids residues required for inhibition (Figure 3C) . The results revealed that the third amino acids residues from the C-terminus, and the C-terminal amino acids having the strongest inhibitory effect were either serine or threonine; and either valine, leucine, or isoleucine, respectively. However, there were no differences among the second amino acid residues from the C-terminus with respect to their inhibitory effect on Fas/FAP-1 binding. These results were consistent with those of the yeast two-hybrid system (Figures 2C and 2D) . Therefore, it was concluded that the C-terminal three amino acids (SLV) are critical determinants of Fas binding to the third PDZ domain of FAP-l protein. To further substantiate that the PDZ domain interacts with tS/T-X-V/L/I under more native conditions, GST- fused FAP-l proteins were tested for their ability to interact with Fas expressed in Jurkat T-cells. The results revealed that the tripeptide Ac-SLV, but not Ac-SLY, abolished in a dose-dependent manner the binding activity of FAP-l to Fas proteins extracted from Jurkat T-cells (Figures 4C and 4D) . This suggests that the C-terminal amino acids tSLV are the minimum binding site for FAP-l, and that the amino acids serine and valine are critical for this physical association. To next examine the hypothesis that the physiological association between the C-terminal three amino acids of Fas and the third PDZ domain of FAP-l is necessary for the in vivo function of FAP-l as a negative regulator of Fas -mediated signal transduction, a microinjection experiment was employed with synthetic tripeptides in a colon cancer cell line, DLD-1, which expresses both Fas and FAP-l, and is resistant to Fas- induced apoptosis. The experiments involved the direct microinjection of the synthetic tripeptides into the cytoplasmic regions of single cells and the monitoring of the physiological response to Fas-induced apoptosis in vivo . The results showed that microinjection of Ac-SLV into DLD-1 cells dramatically induced apoptosis in the presence of Fas-monoclonal antibodies (CH11, 500 ng/ml) (Figures 5A, 5E and Figure 6) , but that microinjection of Ac-SLY and PBS/K did not (Figures 5B, 5F and Figure 6) . These results strongly support the hypothesis that the physical association of FAP-l with the C-terminus of Fas is essential for protecting cells from Fas-induced apoptosis . In summary, it was found that the C-terminal SLV of Fas is alone necessary and sufficient for binding to the third PDZ domain of FAP-l. Secondly, it is proposed that the new consensus motif of tS/T-X-V/L/I for such binding to the PDZ domain, instead of tS/T-X-V. It is therefore possible that FAP-l plays important roles for the modulation of signal transduction pathways in addition to its physical interaction with Fas. Thirdly, it is demonstrated that the targeted induction of Fas-mediated apoptosis in colon cancer cells by direct microinjection of the tripeptide Ac-SLV. Further investigations including the identification of a substrate (s) of FAP-l and structure-function analysis will provide insight to the potential therapeutic applications of Fas/FAP-1 interaction in cancer as well as provide a better understanding of the inhibitory effect of FAP-l on Fas-mediated signal transduction. SECOND SERIES OF EXPERIMENTS FAP-l was originally identified as a membrane-associated protein tyrosine phosphatase which binds to the C- terminus of Fas, and possesses six PDZ domains (also known as DHR domain or GLGF repeat) . PDZ domain has recently been shown as a novel module for specific protein-protein interaction, and it appears to be important in the assembly of membrane proteins and also in linking signaling molecules in a multiprotein complex. In recent comprehensive studies, it was found that the third PDZ domain of FAP-l specifically recognized the sequence motif t (S/T) -X-V and interacts with the C- terminal three amino acids SLV of Fas (Fig. 9) . In order to investigate the possibility that FAP-l also interacts with the C-terminal region of p75NGFR (Fig. 8) , an in vitro binding assay, was performed as well as, a yeast two-hybrid analysis by using a series of deletion mutants of p75NGFR. The results revealed that the C-terminal cytoplasmic region of p75NGFR, which is highly conserved among all species, interacts with FAP-l (Fig. 10) . Furthermore, the C-terminal three amino acids SPV of p75NGFR were necessary and sufficient for the interaction with the third PDZ domain of FAP-l (Fig. 11A and 11B) . Since FAP-l expression was found highest in fetal brain, these findings imply that interaction of FAP-l with p75NGFR plays an important role for signal transduction pathway via p75NGFR in neuronal cells as well as in the formation of the initial signal -transducing complex for p75NGFR. REFERENCES 1. Banville, D. , et al . J. Biol. Chem. 269: 22320-22327 (1994) . 2. Boldin, M. P. et al . J. Biol. Chem. 270: 7795-7798 (1995) . 3. Camerini, D., et al . J . Immunol . 147: 3165-3169 (1991) . 4. Chao, M.V. and B.L. Hempstead TINS 18: 321-326 (1995) . 5. Chinnaiyan, A. M. , et al . Cell 81: 505-512 (1995) . 6. Cho, K.-O., et al. Neuron 9: 929-942 (1992). 7. Conboy, J. G. , et al . J. Biol. Chem. 266: 8273-8280 (1991) . 8. Doyle, D.A., et al . Cell 85: 1067-1076 (1996). 9. Funayama, N. , et al . J. Cell Biol. 115: 1039-1048 (1991) . 10. Gould, K. L., et al . EMBO J. 8: 4133-4142 (1989) . 11. Gu, M. X., et ak. Proc. Natl. Acad. Sci. U.S.A. 88: 5867-5871 (1991) . 12. Hill, D. E., et al. Meth. Enzvmol . 155, 558-568 (1987) . 13. Ito, N., and Nagata, S. J. Biol. Chem. 268: 10932-10937 (1993) . 14. Itoh, N. et al. Cell 66: 233-243 (1991) . 15. Johnson, D. et al . Cell 47: 545-554 (1986) . 16. Kim, E.,et al . Nature 378: 85-88 (1995). 17. Kischkel, F. C. et al . EMBO J. 14: 5579-5588 (1995) 18. Kitamura, K. et al . FEBS Lett. 351: 35-37 (1994) . 19. Kornau, H.-C, et al . Science 269:1737-1740 (1995) 20. Lankes, W. T., and Furthmayr, H. Proc. Natl. Acad. Sci. U.S.A. 88: 8297-8301 (1991). 21. Maekawa, K.. et al . FEBS Letters 337: 200-206 (1994) . 22. Mallett, S., et al . EMBO J. 9: 1063-1068 (1990) . 23. Matsumine, A. et al . Science 272: 1020-1023 (1996) . 24. McGahon, A. J. et al . Meth. Cell Biol. 46: 153-185 (1995) . 25. Pantel, K. et al . J. Natl. Cancer Inst . 87: 1162-1168 (1995) . 26. Rouleau, G. et al . Nature 363: 515-521 (1993) . 27. 28. Sambrook, J., et al.(1989) Molecular Cloning: a laboratory manual. Second Edition. Cold Spring Harbor Laboratory Press . 29. Sato, T., et al . Science 268: 411-415 (1995) . 30. Schnorrenberg, G. and Gerhardt H. Tetrahedron 45: 7759-7764 (1989) . 31. Saras, J., et al . J. Biol. Chem. 269, 24082-24089 (1994) . 32. Smith, C. A. et al . Cell 73: 1349-1360 (1993). 33. Stamenkovic, I., et al . EMBO J . 8: 1403-1410 (1989) . 34. Stanger, B. Z., et al . Cell 81: 513-523 (1995). 35. Takahashi, T. et al . Cell 76: 969-976 (1994) . 36. Vogel, W., et al . (1993) . Science 259: 1611-1614 (1993) . 37. Watanabe-Fukunaga, R. , et al . Nature 356: 314-317 (1992) . 38. Wang, X. W., et al . Cancer Res . 55: 6012-6016 (1995) . 39. Westendorp, M. O. et al . Nature 375: 497-500 (1995) . 40. Woods, D.F. and Bryant, P.J. Cell 66: 451-464 (1991) . 41. Yang, Q. , and Tonks, N. K. Proc. Natl. Acad. Sci U.S.A. 88: 5949-5953 (1991). SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Takaaki Sato and Junn Yanagisawa (ii) TITLE OF INVENTION: COMPOUNDS THAT INHIBIT THE INTERACTION BETWEEN SIGNAL- TRANSDUCING PROTEINS AND THE GLGF (PDZ/DHR) DOMAIN AND USES THEREOF (iii) NUMBER OF SEQUENCES: 33 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Cooper & Dunham LLP (B) STREET: 1185 Avenue of the Americas (C) CITY: New York (D) STATE: New York (E) COUNTRY: U.S.A. (F) ZIP: 10036 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: Not Yet Known (B) FILING DATE: 18-JUL-1997 (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: White, John P (B) REGISTRATION NUMBER: 28,678 (C) REFERENCE/DOCKET NUMBER: 0575/48962-A-PCT/JPW/JKM (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (212) 278-0400 (B) TELEFAX: (212) 391-0525 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: Gly/Ser/Ala/Glu Leu Gly Phe/Ile/Leu 1 (2) INFORMATION FOR SEQ ID NO : 2 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 2 : Lys/Arg/Gln Xa (n) Gly/Ser/Ala/Glu Leu Gly Phe/Ile/Leu 1 5 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: Ser Leu Gly lie 1 (2) INFORMATION FOR SEQ ID NO : 4 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Ser/Thr Xaa Val/Ile/ eu 1 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 5 : Asp Ser Glu Asn Ser Asn Phe Arg Asn Glu lie Gin Ser Leu Val 1 5 10 15 (2) INFORMATION FOR SEQ ID NO : 6 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 6 : Ser lie Ser Asn Ser Arg Asn Glu Asn Glu Gly Gin Ser Leu Glu 1 5 10 15 (2) INFORMATION FOR SEQ ID NO : 7 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 7 : Ser Thr Pro Asp Thr Gly Asn Glu Asn Glu Gly Gin Cys Leu Glu 1 5 10 15 (2) INFORMATION FOR SEQ ID NO : 8 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: Glu Ser Leu Val l (2) INFORMATION FOR SEQ ID NO : 9 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 9 Thr He Gin Ser Val He 1 5 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: Arg Gly Phe He Ser Ser Leu Val 1 5 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: Arg Glu Thr He Glu Ser Thr Val l 5 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: Gin Asn Phe Arg Thr Tyr He Val Ser Phe Val 1 5 10 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi). SEQUENCE DESCRIPTION: SEQ ID NO:13: Ser Asp Ser Asn Met Asn Met Asn Glu Leu Ser Glu Val 1 5 10 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 14 : Pro Pro Thr Cys Ser Gin Ala Asn Ser Gly Arg He Ser Thr Leu 1 5 10 15 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: He Asp Leu Ala Ser Glu Phe Leu Phe Leu Ser Asn Ser Phe Leu 1 5 10 15 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: Asp Ser Glu Met Tyr Asn Phe Arg Ser Gin Leu Ala Ser Val Val 1 5 10 15 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: He Pro Pro Asp Ser Glu Asp Gly Asn Glu Glu Gin Ser Leu Val 1 5 10 15 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: Gin Ser Leu Val 1 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: He Gin Ser Leu Val 1 5 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: Glu He Gin Ser Leu Val 1 5 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: Asn Glu He Gin Ser Leu Val 1 5 (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: Arg Asn Glu He Gin Ser Leu Val 1 5 (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23: Asp Ser Glu Asn Ser Asn Phe Arg Asn Glu He Gin Ser Leu Val 1 5 10 15 (2) INFORMATION FOR SEQ ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 427 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24: Met Gly Ala Gly Ala Thr Gly Arg Ala Met Asp Gly Pro Arg Leu Leu 1 5 10 15 Leu Leu Leu Leu Leu Gly Val Ser Leu Gly Gly Ala Lys Glu Ala Cys 20 25 30 Pro Thr Gly Leu Tyr Thr His Ser Gly Glu Cys Cys Lys Ala Cys Asn 35 40 45 Leu Gly Glu Gly Val Ala Gin Pro Cys Gly Ala Asn Gin Thr Val Cys 50 55 60 Glu Pro Cys Leu Asp Ser Val Thr Phe Ser Asp Val Val Ser Ala Thr 65 70 75 80 Glu Pro Cys Lys Pro Cys Thr Glu Cys Val Gly Leu Gin Ser Met Ser 85 90 95 Ala Pro Cys Val Glu Ala Asp Asp Ala Val Cys Arg Cys Ala Tyr Gly 100 105 110 Tyr Tyr Gin Asp Glu Thr Thr Gly Arg Cys Glu Ala Cys Arg Val Cys 115 120 125 Glu Ala Gly Ser Gly Leu Val Phe Ser Cys Gin Asp Lys Gin Asn Thr 130 135 140 Val Cys Glu Glu Cys Pro Asp Gly Thr Tyr Ser Asp Glu Ala Asn His 145 150 155 160 Val Asp Pro Cys Leu Pro Cys Thr Val Cys Glu Asp Thr Glu Arg Gin 165 170 175 Leu Arg Glu Cys Thr Arg Trp Ala Asp Ala Glu Cys Glu Glu He Pro 180 185 190 Gly Arg Trp He Thr Arg Ser Thr Pro Pro Glu Gly Ser Asp Ser Thr 195 200 205 Ala Pro Ser Thr Gin Glu Pro Glu Ala Pro Pro Glu Gin Asp Leu He 210 215 220 Ala Ser Thr Val Ala Gly Val Val Thr Thr Val Met Gly Ser Ser Gin 225 230 235 240 Pro Val Val Thr Arg Gly Thr Thr Asp Asn Leu He Pro Val Tyr Cys 245 250 255 Ser He Leu Ala Ala Val Val Val Gly Leu Val Ala Tyr He Ala Phe 260 265 270 Lys Arg Trp Asn Ser Cys Lys Gin Asn Lys Gly Gly Ala Asn Ser Arg 275 280 285 Pro Val Asn Gin Thr Pro Pro Pro Glu Gly Glu Lys He His Ser Asp 290 295 300 Ser Gly He Ser Val Asp Ser Gin Ser Leu His Asp Gin Gin Pro His 305 310 315 320 Thr Gin Thr Ala Ser Gly Gin Ala Leu Lys Gly Asp Gly Gly Leu Tyr 325 330 335 Ser Ser Leu Pro Pro Ala Lys Arg Glu Glu Val Glu Lys Leu Leu Asn 340 345 350 Gly Ser Ala Gly Asp Thr Trp Arg His Leu Ala Gly Glu Leu Gly Tyr 355 360 365 Gin Pro Glu His He Asp Ser Phe Thr His Glu Ala Cys Pro Val Arg 370 375 380 Ala Leu Leu Ala Ser Trp Ala Thr Gin Asp Ser Ala Thr Leu Asp Ala 385 390 395 400 Leu Leu Ala Ala Leu Arg Arg He Gin Arg Ala Asp Leu Val Glu Ser 405 410 415 Leu Cys Ser Glu Ser Thr Ala Thr Ser Pro Val 420 425 (2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 458 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: Met Asn Arg Gly Val Pro Phe Arg His Leu Leu Leu Val Leu Gin Leu 1 5 10 15 Ala Leu Leu Pro Ala Ala Thr Gin Gly Lys Lys Val Val Leu Gly Lys 20 25 30 Lys Gly Asp Thr Val Glu Leu Thr Cys Thr Ala Ser Gin Lys Lys Ser 35 40 45 Ile Gin Phe His Trp Lys Asn Ser Asn Gin He Lys He Leu Gly Asn 50 55 60 Gin Gly Ser Phe Leu Thr Lys Gly Pro Ser Lys Leu Asn Asp Arg Ala 65 70 75 80 Asp Ser Arg Arg Ser Leu Trp Asp Gin Gly Asn Phe Pro Leu He He 85 90 95 Lys Asn Leu Lys He Glu Asp Ser Asp Thr Tyr He Cys Glu Val Glu 100 105 110 Asp Gin Lys Glu Glu Val Gin Leu Leu Val Phe Gly Leu Thr Ala Asn 115 120 125 Ser Asp Thr His Leu Leu Gin Gly Gin Ser Leu Thr He Thr Leu Glu 130 135 140 Ser Pro Pro Gly Ser Ser Pro Ser Val Gin Cys Arg Ser Pro Arg Gly 145 150 155 160 Lys Asn He Gin Gly Gly Lys Thr Leu Ser Val Ser Gin Leu Glu Leu 165 170 175 Gin Asp Ser Gly Thr Trp Thr Cys Thr Val Leu Gin Asn Gin Lys Lys 180 185 190 Val Glu Phe Lys He Asp He Val Val Leu Ala Phe Gin Lys Ala Ser 195 200 205 Ser He Val Tyr Lys Lys Glu Gly Glu Gin Val Glu Phe Ser Phe Pro 210 215 220 Leu Ala Phe Thr Val Glu Lys Leu Thr Gly Ser Gly Glu Leu Trp Trp 225 230 235 240 Gin Ala Glu Arg Ala Ser Ser Ser Lys Ser Trp He Thr Phe Asp Leu 245 250 255 Lys Asn Lys Glu Val Ser Val Lys Arg Val Thr Gin Asp Pro Lys Leu 260 265 270 Gin Met Gly Lys Lys Leu Pro Leu His Leu Thr Leu Pro Gin Ala Leu 275 280 285 Pro Gin Tyr Ala Gly Ser Gly Asn Leu Thr Leu Ala Leu Glu Ala Lys 290 295 300 Thr Gly Lys Leu His Gin Glu Asn Val Leu Val Val Met Arg Ala Thr 305 310 315 320 Gin Leu Gin Lys Asn Leu Thr Cys Glu Val Trp Gly Pro Thr Ser Pro 325 330 335 Lys Leu Met Leu Ser Leu Lys Leu Glu Asn Lys Glu Ala Lys Val Ser 340 345 350 Lys Arg Glu Lys Ala Val Trp Val Leu Asn Pro Glu Ala Gly Met Trp 355 360 365 Gin Cys Leu Leu Ser Asp Ser Gly Gin Val Leu Leu Glu Ser Asn He 370 375 380 Lys Val Leu Pro Thr Trp Ser Thr Pro Val Gin Pro Met Ala Leu He 385 390 395 400 Val Leu Gly Gly Val Ala Gly Leu Leu Leu Phe He Gly Leu Gly He 405 410 415 Phe Phe Cys Val Arg Cys Arg His Arg Arg Arg Gin Ala Glu Arg Met 420 425 430 Ser Gin He Lys Arg Leu Leu Ser Glu Lys Lys Glu Cys Gin Cys Pro 435 440 445 His Arg Phe Gin Lys Thr Cys Ser Pro He 450 455 (2) INFORMATION FOR SEQ ID NO: 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 828 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: Met Asn Ser Gly Val Ala Met Lys Tyr Gly Asn Asp Ser Ser Ala Glu 1 5 10 15 Leu Ser Glu Leu His Ser Ala Ala Leu Ala Ser Leu Lys Gly Asp He 20 25 30 Val Glu Leu Asn Lys Arg Leu Gin Gin Thr Glu Arg Glu Asp Leu Leu 35 40 45 Glu Lys Lys Leu Ala Lys Ala Gin Cys Glu Gin Ser His Leu Met Arg 50 55 60 Glu His Glu Asp Val Gin Glu Arg Thr Thr Leu Arg Tyr Glu Glu Arg 65 70 75 80 He Thr Glu Leu His Ser Val He Ala Glu Leu Asn Lys Lys He Asp 85 90 95 Arg Leu Gin Gly Thr Thr He Arg Glu Glu Asp Glu Tyr Ser Glu Leu 100 105 110 Arg Ser Glu Leu Ser Gin Ser Gin His Glu Val Asn Glu Asp Ser Arg 115 120 125 Ser Met Asp Gin Asp Gin Thr Ser Val Ser He Pro Glu Asn Gin Ser 130 135 140 Thr Met Val Thr Ala Asp Met Asp Asn Cys Ser Asp He Asn Ser Glu 145 150 155 160 Leu Gin Arg Val Leu Thr Gly Leu Glu Asn Val Val Cys Gly Arg Lys 165 170 175 Lys Ser Ser Cys Ser Leu Ser Val Ala Glu Val Asp Arg His He Glu 180 185 190 Gin Leu Thr Thr Ala Ser Glu His Cys Asp Leu Ala He Lys Thr Val 195 200 205 Glu Glu He Glu Gly Val Leu Gly Arg Asp Leu Tyr Pro Asn Leu Ala 210 215 220 Glu Glu Arg Ser Arg Trp Glu Lys Glu Leu Ala Gly Leu Arg Glu Glu 225 230 235 240 Asn Glu Ser Leu Thr Ala Met Leu Cys Ser Lys Glu Glu Glu Leu Asn 245 250 255 Arg Thr Lys Ala Thr Met Asn Ala He Arg Glu Glu Arg Asp Arg Leu 260 265 270 Arg Arg Arg Val Arg Glu Leu Gin Thr Arg Leu Gin Ser Val Gin Ala 275 280 285 Thr Gly Pro Ser Ser Pro Gly Arg Leu Thr Ser Thr Asn Arg Pro He 290 295 300 Asn Pro Ser Thr Gly Glu Leu Ser Thr Ser Ser Ser Ser Asn Asp He 305 310 315 320 Pro He Ala Lys He Ala Glu Arg Val Lys Leu Ser Lys Thr Arg Ser 325 330 335 Glu Ser Ser Ser Ser Asp Arg Pro Val Leu Gly Ser Glu He Ser Ser 340 345 350 He Gly Val Ser Ser Ser Val Ala Glu His Leu Ala His Ser Leu Gin 355 360 365 Asp Cys Ser Asn He Gin Glu He Phe Gin Thr Leu Tyr Ser His Gly 370 375 380 Ser Ala He Ser Glu Ser Lys He Arg Glu Phe Glu Val Glu Thr Glu 385 390 395 400 Arg Leu Asn Ser Arg He Glu His Leu Lys Ser Gin Asn Asp Leu Leu 405 410 415 Thr He Thr Leu Glu Glu Cys Lys Ser Asn Ala Glu Arg Met Ser Met 420 425 430 Leu Val Gly Lys Tyr Glu Ser Asn Ala Thr Ala Leu Arg Leu Ala Leu 435 440 445 Gin Tyr Ser Glu Gin Cys He Glu Ala Tyr Glu Leu Leu Leu Ala Leu 450 455 460 Ala Glu Ser Glu Gin Ser Leu He Leu Gly Gin Phe Arg Ala Ala Gly 465 470 475 480 Val Gly Ser Ser Pro Gly Asp Gin Ser Gly Asp Glu Asn He Thr Gin 485 490 495 Met Leu Lys Arg Ala His Asp Cys Arg Lys Thr Ala Glu Asn Ala Ala 500 505 510 Lys Ala Leu Leu Met Lys Leu Asp Gly Ser Cys Gly Gly Ala Phe Ala 515 520 525 Val Ala Gly Cys Ser Val Gin Pro Trp Glu Ser Leu Ser Ser Asn Ser 530 535 540 His Thr Ser Thr Thr Ser Ser Thr Ala Ser Ser Cys Asp Thr Glu Phe 545 550 555 560 Thr Lys Glu Asp Glu Gin Arg Leu Lys Asp Tyr He Gin Gin Leu Lys 565 570 575 Asn Asp Arg Ala Ala Val Lys Leu Thr Met Leu Glu Leu Glu Ser He 580 585 590 His He Asp Pro Leu Ser Tyr Asp Val Lys Pro Arg Gly Asp Ser Gin 595 600 605 Arg Leu Asp Leu Glu Asn Ala Val Leu Met Gin Glu Leu Met Ala Met 610 615 620 Lys Glu Glu Met Ala Glu Leu Lys Ala Gin Leu Tyr Leu Leu Glu Lys 625 630 635 640 Glu Lys Lys Ala Leu Glu Leu Lys Leu Ser Thr Arg Glu Ala Gin Glu 645 650 655 Gin Ala Tyr Leu Val His He Glu His Leu Lys Ser Glu Val Glu Glu 660 665 670 Gin Lys Glu Gin Arg Met Arg Ser Leu Ser Ser Thr Ser Ser Gly Ser 675 680 685 Lys Asp Lys Pro Gly Lys Glu Cys Ala Asp Ala Ala Ser Pro Ala Leu 690 695 700 Ser Leu Ala Glu Leu Arg Thr Thr Cys Ser Glu Asn Glu Leu Ala Ala 705 710 715 720 Glu Phe Thr Asn Ala He Arg Arg Glu Lys Lys Leu Lys Ala Arg Val 725 730 735 Gin Glu Leu Val Ser Ala Leu Glu Arg Leu Thr Lys Ser Ser Glu He 740 745 750 Arg His Gin Gin Ser Ala Glu Phe Val Asn Asp Leu Lys Arg Ala Asn 755 760 765 Ser Asn Leu Val Ala Ala Tyr Glu Lys Ala Lys Lys Lys His Gin Asn 770 775 780 Lys Leu Lys Lys Leu Glu Ser Gin Met Met Ala Met Val Glu Arg His 785 790 795 800 Glu Thr Gin Val Arg Met Leu Lys Gin Arg He Ala Leu Leu Glu Glu 805 810 815 Glu Asn Ser Arg Pro His Thr Asn Glu Thr Ser Leu 820 825 (2) INFORMATION FOR SEQ ID NO: 27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 672 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: Met Ala Asp Val Phe Pro Gly Asn Asp Ser Thr Ala Ser Gin Asp Val 1 5 10 15 Ala Asn Arg Phe Ala Arg Lys Gly Ala Leu Arg Gin Lys Asn Val His 20 25 30 Glu Val Lys Asp His Lys Phe He Ala Arg Phe Phe Lys Gin Pro Thr 35 40 45 Phe Cys Ser His Cys Thr Asp Phe He Trp Gly Phe Gly Lys Gly Gly 50 55 60 Phe Gin Cys Gin Val Cys Cys Phe Val Val His Lys Arg Cys His Glu 65 70 75 80 Phe Val Thr Phe Ser Cys Pro Gly Ala Asp Lys Gly Pro Asp Thr Asp 85 90 95 Asp Pro Arg Ser Lys His Lys Phe Lys He His Thr Tyr Gly Ser Pro 100 105 110 Thr Phe Cys Asp His Cys Gly Ser Leu Leu Tyr Gly Leu He His Gin 115 120 125 Gly Met Lys Cys Asp Thr Cys Asp Met Asn Val His Lys Gin Cys Val 130 135 140 He Asn Val Pro Ser Leu Cys Gly Met Asp His Thr Glu Lys Arg Gly 145 150 155 160 Arg He Tyr Leu Lys Ala Glu Val Ala Asp Glu Lys Leu His Val Thr 165 170 175 Val Arg Asp Ala Lys Asn Leu He Pro Met Asp Pro Asn Gly Leu Ser 180 185 190 Asp Pro Tyr Val Lys Leu Lys Leu He Pro Asp Pro Lys Asn Glu Ser 195 200 205 Lys Gin Lys Thr Lys Thr He Arg Ser Thr Leu Asn Pro Gin Trp Asn 210 215 220 Glu Ser Phe Thr Phe Lys Leu Lys Pro Ser Asp Lys Asp Arg Arg Leu 225 230 235 240 Ser Val Glu He Trp Asp Trp Asp Arg Thr Thr Arg Asn Asp Phe Met 245 250 255 Gly Ser Leu Ser Phe Gly Val Ser Glu Leu Met Lys Met Pro Ala Ser 260 265 270 Gly Trp Tyr Lys Leu Leu Asn Gin Glu Glu Gly Glu Tyr Tyr Asn Val 275 280 285 Pro He Pro Glu Gly Asp Glu Glu Gly Asn Met Glu Leu Arg Gin Lys 290 295 300 Phe Glu Lys Ala Lys Leu Gly Pro Ala Gly Asn Lys Val He Ser Pro 305 310 315 320 Ser Glu Asp Arg Lys Gin Pro Ser Asn Asn Leu Asp Arg Val Lys Leu 325 330 335 Thr Asp Phe Asn Phe Leu Met Val Leu Gly Lys Gly Ser Phe Gly Lys 340 345 350 Val Met Leu Ala Asp Arg Lys Gly Thr Glu Glu Leu Tyr Ala He Lys 355 360 365 He Leu Lys Lys Asp Val Val He Gin Asp Asp Asp Val Glu Cys Thr 370 375 380 Met Val Glu Lys Arg Val Leu Ala Leu Leu Asp Lys Pro Pro Phe Leu 385 390 395 400 Thr Gin Leu His Ser Cys Phe Gin Thr Val Asp Arg Leu Tyr Phe Val 405 410 415 Met Glu Tyr Val Asn Gly Gly Asp Leu Met Tyr His He Gin Gin Val 420 425 430 Gly Lys Phe Lys Glu Pro Gin Ala Val Phe Tyr Ala Ala Glu He Ser 435 440 445 He Gly Leu Phe Phe Leu His Lys Arg Gly He He Tyr Arg Asp Leu 450 455 460 Lys Leu Asp Asn Val Met Leu Asp Ser Glu Gly His He Lys He Ala 465 470 475 480 Asp Phe Gly Met Cys Lys Glu His Met Met Asp Gly Val Thr Thr Arg 485 490 495 Thr Phe Cys Gly Thr Pro Asp Tyr He Ala Pro Glu He He Ala Tyr 500 505 510 Gin Pro Tyr Gly Lys Ser Val Asp Trp Trp Ala Tyr Gly Val Leu Leu 515 520 525 Tyr Glu Met Leu Ala Gly Gin Pro Pro Phe Asp Gly Glu Asp Glu Asp 530 535 540 Glu Leu Phe Gin Ser He Met Glu His Asn Val Ser Tyr Pro Lys Ser 545 550 555 560 Leu Ser Lys Glu Ala Val Ser He Cys Lys Gly Leu Met Thr Lys His 565 570 575 Pro Ala Lys Arg Leu Gly Cys Gly Pro Glu Gly Glu Arg Asp Val Arg 580 585 590 Glu His Ala Phe Phe Arg Arg He Asp Trp Glu Lys Leu Glu Asn Arg 595 600 605 Glu He Gin Pro Pro Phe Lys Pro Lys Val Cys Gly Lys Gly Ala Glu 610 615 620 Asn Phe Asp Lys Phe Phe Thr Arg Gly Gin Pro Val Leu Thr Pro Pro 625 630 635 640 Asp Gin Leu Val He Ala Asn He Asp Gin Ser Asp Phe Glu Gly Phe 645 650 655 Ser Tyr Val Asn Pro Gin Phe Val His Pro He Leu Gin Ser Ala Val 660 665 670 (2 ) INFORMATION FOR SEQ ID NO : 28 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 471 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: Met Asp He Leu Cys Glu Glu Asn Thr Ser Leu Ser Ser Thr Thr Asn 1 5 10 15 Ser Leu Met Gin Leu Asn Asp Asp Thr Arg Leu Tyr Ser Asn Asp Phe 20 25 30 Asn Ser Gly Glu Ala Asn Thr Ser Asp Ala Phe Asn Trp Thr Val Asp 35 40 45 Ser Glu Asn Arg Thr Asn Leu Ser Cys Glu Gly Cys Leu Ser Pro Ser 50 55 60 Cys Leu Ser Leu Leu His Leu Gin Glu Lys Asn Trp Ser Ala Leu Leu 65 70 75 80 Thr Ala Val Val He He Leu Thr He Ala Gly Asn He Leu Val He 85 90 95 Met Ala Val Ser Leu Glu Lys Lys Leu Gin Asn Ala Thr Asn Tyr Phe 100 105 110 Leu Met Ser Leu Ala He Ala Asp Met Leu Leu Gly Phe Leu Val Met 115 120 125 Pro Val Ser Met Leu Thr He Leu Tyr Gly Tyr Arg Trp Pro Leu Pro 130 135 140 Ser Lys Leu Cys Ala Val Trp He Tyr Leu Asp Val Leu Phe Ser Thr 145 150 155 160 Ala Ser He Met His Leu Cys Ala He Ser Leu Asp Arg Tyr Val Ala 165 170 175 He Gin Asn Pro He His His Ser Arg Phe Asn Ser Arg Thr Lys Ala 180 185 190 Phe Leu Lys He He Ala Val Trp Thr He Ser Val Gly He Ser Met 195 200 205 Pro He Pro Val Phe Gly Leu Gin Asp Asp Ser Lys Val Phe Lys Glu 210 215 220 Gly Ser Cys Leu Leu Ala Asp Asp Asn Phe Val Leu He Gly Ser Phe 225 230 235 240 Val Ser Phe Phe He Pro Leu Thr He Met Val He Thr Tyr Phe Leu 245 250 255 Thr He Lys Ser Leu Gin Lys Glu Ala Thr Leu Cys Val Ser Asp Leu 260 265 270 Gly Thr Arg Ala Lys Leu Ala Ser Phe Ser Phe Leu Pro Gin Ser Ser 275 280 285 Leu Ser Ser Glu Lys Leu Phe Gin Arg Ser He His Arg Glu Pro Gly 290 295 300 Ser Tyr Thr Gly Arg Arg Thr Met Gin Ser He Ser Asn Glu Gin Lys 305 310 315 320 Ala Cys Lys Val Leu Gly He Val Phe Phe Leu Phe Val Val Met Trp 325 330 335 Cys Pro Phe Phe He Thr Asn He Met Ala Val He Cys Lys Glu Ser 340 345 350 Cys Asn Glu Asp Val He Gly Ala Leu Leu Asn Val Phe Val Trp He 355 360 365 Gly Tyr Leu Ser Ser Ala Val Asn Pro Leu Val Tyr Thr Leu Phe Asn 370 375 380 Lys Thr Tyr Arg Ser Ala Phe Ser Arg Tyr He Gin Cys Gin Tyr Lys 385 390 395 400 Glu Asn Lys Lys Pro Leu Gin Leu He Leu Val Asn Thr He Pro Ala 405 410 415 Leu Ala Tyr Lys Ser Ser Gin Leu Gin Met Gly Gin Lys Lys Asn Ser 420 425 430 Lys Gin Asp Ala Lys Thr Thr Asp Asn Asp Cys Ser Met Val Ala Leu 435 440 445 Gly Lys Gin His Ser Glu Glu Ala Ser Lys Asp Asn Ser Asp Gly Val 450 455 460 Asn Glu Lys Val Ser Cys Val 465 470 (2) INFORMATION FOR SEQ ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 481 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29: Met Ala Leu Ser Tyr Arg Val Ser Glu Leu Gin Ser Thr He Pro Glu 1 5 10 15 His He Leu Gin Ser Thr Phe Val His Val He Ser Ser Asn Trp Ser 20 25 30 Gly Leu Gin Thr Glu Ser He Pro Glu Glu Met Lys Gin He Val Glu 35 40 45 Glu Gin Gly Asn Lys Leu His Trp Ala Ala Leu Leu He Leu Met Val 50 55 60 He He Pro Thr He Gly Gly Asn Thr Leu Val He Leu Ala Val Ser 65 70 75 80 Leu Glu Lys Lys Leu Gin Tyr Ala Thr Asn Tyr Phe Leu Met Ser Leu 85 90 95 Ala Val Ala Asp Leu Leu Val Gly Leu Phe Val Met Pro He Ala Leu 100 105 110 Leu Thr He Met Phe Glu Ala Met Trp Pro Leu Pro Leu Val Leu Cys 115 120 125 Pro Ala Trp Leu Phe Leu Asp Val Leu Phe Ser Thr Ala Ser He Met 130 135 140 His Leu Cys Ala He Ser Val Asp Arg Tyr He Ala He Lys Lys Pro 145 150 155 160 He Gin Ala Asn Gin Tyr Asn Ser Arg Ala Thr Ala Phe He Lys He 165 170 175 Thr Val Val Trp Leu He Ser He Gly He Ala He Pro Val Pro He 180 185 190 Lys Gly He Glu Thr Asp Val Asp Asn Pro Asn Asn He Thr Cys Val 195 200 205 Leu Thr Lys Glu Arg Phe Gly Asp Phe Met Leu Phe Gly Ser Leu Ala 210 215 220 Ala Phe Phe Thr Pro Leu Ala He Met He Val Thr Tyr Phe Leu Thr 225 230 235 240 He His Ala Leu Gin Lys Lys Ala Tyr Leu Val Lys Asn Lys Pro Pro 245 250 255 Gin Arg Leu Thr Trp Leu Thr Val Ser Thr Val Phe Gin Arg Asp Glu 260 265 270 Thr Pro Cys Ser Ser Pro Glu Lys Val Ala Met Leu Asp Gly Ser Arg 275 280 285 Lys Asp Lys Ala Leu Pro Asn Ser Gly Asp Glu Thr Leu Met Arg Arg 290 295 300 Thr Ser Thr He Gly Lys Lys Ser Val Gin Thr He Ser Asn Glu Gin 305 310 315 320 Arg Ala Ser Lys Val Leu Gly He Val Phe Phe Leu Phe Leu Leu Met 325 330 335 Trp Cys Pro Phe Phe He Thr Asn He Thr Leu Val Leu Cys Asp Ser 340 345 350 Cys Asn Gin Thr Thr Leu Gin Met Leu Leu Glu He Phe Val Trp He 355 360 365 Gly Tyr Val Ser Ser Gly Val Asn Pro Leu Val Tyr Thr Leu Phe Asn 370 375 380 Lys Thr Phe Arg Asp Ala Phe Gly Arg Tyr He Thr Cys Asn Tyr Arg 385 390 395 400 Ala Thr Lys Ser Val Lys Thr Leu Arg Lys Arg Ser Ser Lys He Tyr 405 410 415 Phe Arg Asn Pro Met Ala Glu Asn Ser Lys Phe Phe Lys Lys His Gly 420 425 430 He Arg Asn Gly He Asn Pro Ala Met Tyr Gin Ser Pro Met Arg Leu 435 440 445 Arg Ser Ser Thr He Gin Ser Ser Ser He He Leu Leu Asp Thr Leu 450 455 460 Leu Leu Thr Glu Asn Glu Gly Asp Lys Thr Glu Glu Gin Val Ser Val 465 470 475 480 Val (2) INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2843 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: Met Ala Ala Ala Ser Tyr Asp Gin Leu Leu Lys Gin Val Glu Ala Leu 1 5 10 15 Lys Met Glu Asn Ser Asn Leu Arg Gin Glu Leu Glu Asp Asn Ser Asn 20 25 30 His Leu Thr Lys Leu Glu Thr Glu Ala Ser Asn Met Lys Glu Val Leu 35 40 45 Lys Gin Leu Gin Gly Ser He Glu Asp Glu Ala Met Ala Ser Ser Gly 50 55 60 Gin He Asp Leu Leu Glu Arg Leu Lys Glu Leu Asn Leu Asp Ser Ser 65 70 75 80 Asn Phe Pro Gly Val Lys Leu Arg Ser Lys Met Ser Leu Arg Ser Tyr 85 90 95 Gly Ser Arg Glu Gly Ser Val Ser Ser Arg Ser Gly Glu Cys Ser Pro 100 105 110 Val Pro Met Gly Ser Phe Pro Arg Arg Gly Phe Val Asn Gly Ser Arg 115 120 125 Glu Ser Thr Gly Tyr Leu Glu Glu Leu Glu Lys Glu Arg Ser Leu Leu 130 135 140 Leu Ala Asp Leu Asp Lys Glu Glu Lys Glu Lys Asp Trp Tyr Tyr Ala 145 150 155 160 Gin Leu Gin Asn Leu Thr Lys Arg He Asp Ser Leu Pro Leu Thr Glu 165 170 175 Asn Phe Ser Leu Gin Thr Asp Met Thr Arg Arg Gin Leu Glu Tyr Glu 180 185 190 Ala Arg Gin He Arg Val Ala Met Glu Glu Gin Leu Gly Thr Cys Gin 195 200 205 Asp Met Glu Lys Arg Ala Gin Arg Arg He Ala Arg He Gin Gin He 210 215 220 Glu Lys Asp He Leu Arg He Arg Gin Leu Leu Gin Ser Gin Ala Thr 225 230 235 240 Glu Ala Glu Arg Ser Ser Gin Asn Lys His Glu Thr Gly Ser His Asp 245 250 255 Ala Glu Arg Gin Asn Glu Gly Gin Gly Val Gly Glu He Asn Met Ala 260 265 270 Thr Ser Gly Asn Gly Gin Gly Ser Thr Thr Arg Met Asp His Glu Thr 275 280 285 Ala Ser Val Leu Ser Ser Ser Ser Thr His Ser Ala Pro Arg Arg Leu 290 295 300 Thr Ser His Leu Gly Thr Lys Val Glu Met Val Tyr Ser Leu Leu Ser 305 310 315 320 Met Leu Gly Thr His Asp Lys Asp Asp Met Ser Arg Thr Leu Leu Ala 325 330 335 Met Ser Ser Ser Gin Asp Ser Cys He Ser Met Arg Gin Ser Gly Cys 340 345 350 Leu Pro Leu Leu He Gin Leu Leu His Gly Asn Asp Lys Asp Ser Val 355 360 365 Leu Leu Gly Asn Ser Arg Gly Ser Lys Glu Ala Arg Ala Arg Ala Ser 370 375 380 Ala Ala Leu His Asn He He His Ser Gin Pro Asp Asp Lys Arg Gly 385 390 395 400 Arg Arg Glu He Arg Val Leu His Leu Leu Glu Gin He Arg Ala Tyr 405 410 415 Cys Ser Thr Cys Trp Glu Trp Gin Glu Ala His Glu Pro Gly Met Asp 420 425 430 Gin Asp Lys Asn Pro Met Pro Ala Pro Val Glu His Gin He Cys Pro 435 440 445 Ala Val Cys Val Leu Met Lys Leu Ser Phe Asp Glu Glu His Arg His 450 455 460 Ala Met Asn Glu Leu Gly Gly Leu Gin Ala He Ala Glu Leu Leu Gin 465 470 475 480 Val Asp Cys Glu Met Tyr Gly Leu Thr Asn Asp His Tyr Ser He Thr 485 490 495 Leu Arg Arg Tyr Ala Gly Met Ala Leu Thr Asn Leu Thr Phe Gly Asp 500 505 510 Val Ala Asn Lys Ala Thr Leu Cys Ser Met Lys Gly Cys Met Arg Ala 515 520 525 Leu Val Ala Gin Leu Lys Ser Glu Ser Glu Asp Leu Gin Gin Val He 530 535 540 Ala Ser Val Leu Arg Asn Leu Ser Trp Arg Ala Asp Val Asn Ser Lys 545 550 555 560 Lys Thr Leu Arg Glu Val Gly Ser Val Lys Ala Leu Met Glu Cys Ala 565 570 575 Leu Glu Val Lys Lys Glu Ser Thr Leu Lys Ser Val Leu Ser Ala Leu 580 585 590 Trp Asn Leu Ser Ala His Cys Thr Glu Asn Lys Ala Asp He Cys Ala 595 600 605 Val Asp Gly Ala Leu Ala Phe Leu Val Gly Thr Leu Thr Tyr Arg Ser 610 615 620 Gin Thr Asn Thr Leu Ala He He Glu Ser Gly Gly Gly He Leu Arg 625 630 635 640 Asn Val Ser Ser Leu He Ala Thr Asn Glu Asp His Arg Gin He Leu 645 650 655 Arg Glu Asn Asn Cys Leu Gin Thr Leu Leu Gin His Leu Lys Ser His 660 665 670 Ser Leu Thr He Val Ser Asn Ala Cys Gly Thr Leu Trp Asn Leu Ser 675 680 685 Ala Arg Asn Pro Lys Asp Gin Glu Ala Leu Trp Asp Met Gly Ala Val 690 695 700 Ser Met Leu Lys Asn Leu He His Ser Lys His Lys Met He Ala Met 705 710 715 720 Gly Ser Ala Ala Ala Leu Arg Asn Leu Met Ala Asn Arg Pro Ala Lys 725 730 735 Tyr Lys Asp Ala Asn He Met Ser Pro Gly Ser Ser Leu Pro Ser Leu 740 745 750 His Val Arg Lys Gin Lys Ala Leu Glu Ala Glu Leu Asp Ala Gin His 755 760 765 Leu Ser Glu Thr Phe Asp Asn He Asp Asn He Ser Pro Lys Ala Ser 770 775 780 His Arg Ser Lys Gin Arg His Lys Gin Ser Leu Tyr Gly Asp Tyr Val 785 790 795 800 Phe Asp Thr Asn Arg His Asp Asp Asn Arg Ser Asp Asn Phe Asn Thr 805 810 815 Gly Asn Met Thr Val Leu Ser Pro Tyr Leu Asn Thr Thr Val Leu Pro 820 825 830 Ser Ser Ser Ser Ser Arg Gly Ser Leu Asp Ser Ser Arg Ser Glu Lys 835 840 845 Asp Arg Ser Leu Glu Arg Glu Arg Gly He Gly Leu Gly Asn Tyr His 850 855 860 Pro Ala Thr Glu Asn Pro Gly Thr Ser Ser Lys Arg Gly Leu Gin He 865 870 875 880 Ser Thr Thr Ala Ala Gin He Ala Lys Val Met Glu Glu Val Ser Ala 885 890 895 He His Thr Ser Gin Glu Asp Arg Ser Ser Gly Ser Thr Thr Glu Leu 900 905 910 His Cys Val Thr Asp Glu Arg Asn Ala Leu Arg Arg Ser Ser Ala Ala 915 920 925 His Thr His Ser Asn Thr Tyr Asn Phe Thr Lys Ser Glu Asn Ser Asn 930 935 940 Arg Thr Cys Ser Met Pro Tyr Ala Lys Leu Glu Tyr Lys Arg Ser Ser 945 950 955 960 Asn Asp Ser Leu Asn Ser Val Ser Ser Ser Asp Gly Tyr Gly Lys Arg 965 970 975 Gly Gin Met Lys Pro Ser He Glu Ser Tyr Ser Glu Asp Asp Glu Ser 980 985 990 Lys Phe Cys Ser Tyr Gly Gin Tyr Pro Ala Asp Leu Ala His Lys He 995 1000 1005 His Ser Ala Asn His Met Asp Asp Asn Asp Gly Glu Leu Asp Thr Pro 1010 1015 1020 He Asn Tyr Ser Leu Lys Tyr Ser Asp Glu Gin Leu Asn Ser Gly Arg 1025 1030 1035 1040 Gin Ser Pro Ser Gin Asn Glu Arg Trp Ala Arg Pro Lys His He He 1045 1050 1055 Glu Asp Glu He Lys Gin Ser Glu Gin Arg Gin Ser Arg Asn Gin Ser 1060 1065 1070 Thr Thr Tyr Pro Val Tyr Thr Glu Ser Thr Asp Asp Lys His Leu Lys 1075 1080 1085 Phe Gin Pro His Phe Gly Gin Gin Glu Cys Val Ser Pro Tyr Arg Ser 1090 1095 1100 Arg Gly Ala Asn Gly Ser Glu Thr Asn Arg Val Gly Ser Asn His Gly 1105 1110 1115 1120 He Asn Gin Asn Val Ser Gin Ser Leu Cys Gin Glu Asp Asp Tyr Glu 1125 1130 1135 Asp Asp Lys Pro Thr Asn Tyr Ser Glu Arg Tyr Ser Glu Glu Glu Gin 1140 1145 1150 His Glu Glu Glu Glu Arg Pro Thr Asn Tyr Ser He Lys Tyr Asn Glu 1155 1160 1165 Glu Lys Arg His Val Asp Gin Pro He Asp Tyr Ser He Leu Lys Ala 1170 1175 1180 Thr Asp He Pro Ser Ser Gin Lys Gin Ser Phe Ser Phe Ser Lys Ser 1185 1190 1195 1200 Ser Ser Gly Gin Ser Ser Lys Thr Glu His Met Ser Ser Ser Ser Glu 1205 1210 1215 Asn Thr Ser Thr Pro Ser Ser Asn Ala Lys Arg Gin Asn Gin Leu His 1220 1225 1230 Pro Ser Ser Ala Gin Ser Arg Ser Gly Gin Pro Gin Lys Ala Ala Thr 1235 1240 1245 Cys Lys Val Ser Ser He Asn Gin Glu Thr He Gin Thr Tyr Cys Val 1250 1255 1260 Glu Asp Thr Pro He Cys Phe Ser Arg Cys Ser Ser Leu Ser Ser Leu 1265 1270 1275 1280 Ser Ser Ala Glu Asp Glu He Gly Cys Asn Gin Thr Thr Gin Glu Ala 1285 1290 1295 Asp Ser Ala Asn Thr Leu Gin He Ala Glu He Lys Glu Lys He Gly 1300 1305 1310 Thr Arg Ser Ala Glu Asp Pro Val Ser Glu Val Pro Ala Val Ser Gin 1315 1320 1325 His Pro Arg Thr Lys Ser Ser Arg Leu Gin Gly Ser Ser Leu Ser Ser 1330 1335 1340 Glu Ser Ala Arg His Lys Ala Val Glu Phe Ser Ser Gly Ala Lys Ser 1345 1350 1355 1360 Pro Ser Lys Ser Gly Ala Gin Thr Pro Lys Ser Pro Pro Glu His Tyr 1365 1370 1375 Val Gin Glu Thr Pro Leu Met Phe Ser Arg Cys Thr Ser Val Ser Ser 1380 1385 1390 Leu Asp Ser Phe Glu Ser Arg Ser He Ala Ser Ser Val Gin Ser Glu 1395 1400 1405 Pro Cys Ser Gly Met Val Ser Gly He He Ser Pro Ser Asp Leu Pro 1410 1415 1420 Asp Ser Pro Gly Gin Thr Met Pro Pro Ser Arg Ser Lys Thr Pro Pro 1425 1430 1435 1440 Pro Pro Pro Gin Thr Ala Gin Thr Lys Arg Glu Val Pro Lys Asn Lys 1445 1450 1455 Ala Pro Thr Ala Glu Lys Arg Glu Ser Gly Pro Lys Gin Ala Ala Val 1460 1465 1470 Asn Ala Ala Val Gin Arg Val Gin Val Leu Pro Asp Ala Asp Thr Leu 1475 1480 1485 Leu His Phe Ala Thr Glu Ser Thr Pro Asp Gly Phe Ser Cys Ser Ser 1490 1495 1500 Ser Leu Ser Ala Leu Ser Leu Asp Glu Pro Phe He Gin Lys Asp Val 1505 1510 1515 1520 Glu Leu Arg He Met Pro Pro Val Gin Glu Asn Asp Asn Gly Asn Glu 1525 1530 1535 Thr Glu Ser Glu Gin Pro Lys Glu Ser Asn Glu Asn Gin Glu Lys Glu 1540 1545 1550 Ala Glu Lys Thr He Asp Ser Glu Lys Asp Leu Leu Asp Asp Ser Asp 1555 1560 1565 Asp Asp Asp He Glu He Leu Glu Glu Cys He He Ser Ala Met Pro 1570 1575 1580 Thr Lys Ser Ser Arg Lys Ala Lys Lys Pro Ala Gin Thr Ala Ser Lys 1585 1590 1595 1600 Leu Pro Pro Pro Val Ala Arg Lys Pro Ser Gin Leu Pro Val Tyr Lys 1605 1610 1615 Leu Leu Pro Ser Gin Asn Arg Leu Gin Pro Gin Lys His Val Ser Phe 1620 1625 1630 Thr Pro Gly Asp Asp Met Pro Arg Val Tyr Cys Val Glu Gly Thr Pro 1635 1640 1645 He Asn Phe Ser Thr Ala Thr Ser Leu Ser Asp Leu Thr He Glu Ser 1650 1655 1660 Pro Pro Asn Glu Leu Ala Ala Gly Glu Gly Val Arg Gly Gly Ala Gin 1665 1670 1675 1680 Ser Gly Glu Phe Glu Lys Arg Asp Thr He Pro Thr Glu Gly Arg Ser 1685 1690 1695 Thr Asp Glu Ala Gin Gly Gly Lys Thr Ser Ser Val Thr He Pro Glu 1700 1705 1710 Leu Asp Asp Asn Lys Ala Glu Glu Gly Asp He Leu Ala Glu Cys He 1715 1720 1725 Asn Ser Ala Met Pro Lys Gly Lys Ser His Lys Pro Phe Arg Val Lys 1730 1735 1740 Lys He Met Asp Gin Val Gin Gin Ala Ser Ala Ser Ser Ser Ala Pro 1745 1750 1755 1760 Asn Lys Asn Gin Leu Asp Gly Lys Lys Lys Lys Pro Thr Ser Pro Val 1765 1770 1775 Lys Pro He Pro Gin Asn Thr Glu Tyr Arg Thr Arg Val Arg Lys Asn 1780 1785 1790 Ala Asp Ser Lys Asn Asn Leu Asn Ala Glu Arg Val Phe Ser Asp Asn 1795 1800 1805 Lys Asp Ser Lys Lys Gin Asn Leu Lys Asn Asn Ser Lys Asp Phe Asn 1810 1815 1820 Asp Lys Leu Pro Asn Asn Glu Asp Arg Val Arg Gly Ser Phe Ala Phe 1825 1830 1835 1840 Asp Ser Pro His His Tyr Thr Pro He Glu Gly Thr Pro Tyr Cys Phe 1845 1850 1855 Ser Arg Asn Asp Ser Leu Ser Ser Leu Asp Phe Asp Asp Asp Asp Val 1860 1865 1870 Asp Leu Ser Arg Glu Lys Ala Glu Leu Arg Lys Ala Lys Glu Asn Lys 1875 1880 1885 Glu Ser Glu Ala Lys Val Thr Ser His Thr Glu Leu Thr Ser Asn Gin 1890 1895 1900 Gin Ser Ala Asn Lys Thr Gin Ala He Ala Lys Gin Pro He Asn Arg 1905 1910 1915 1920 Gly Gin Pro Lys Pro He Leu Gin Lys Gin Ser Thr Phe Pro Gin Ser 1925 1930 1935 Ser Lys Asp He Pro Asp Arg Gly Ala Ala Thr Asp Glu Lys Leu Gin 1940 1945 1950 Asn Phe Ala He Glu Asn Thr Pro Val Cys Phe Ser His Asn Ser Ser 1955 1960 1965 Leu Ser Ser Leu Ser Asp He Asp Gin Glu Asn Asn Asn Lys Glu Asn 1970 1975 1980 Glu Pro He Lys Glu Thr Glu Pro Pro Asp Ser Gin Gly Glu Pro Ser 1985 1990 1995 2000 Lys Pro Gin Ala Ser Gly Tyr Ala Pro Lys Ser Phe His Val Glu Asp 2005 2010 2015 Thr Pro Val Cys Phe Ser Arg Asn Ser Ser Leu Ser Ser Leu Ser He 2020 2025 2030 Asp Ser Glu Asp Asp Leu Leu Gin Glu Cys He Ser Ser Ala Met Pro 2035 2040 2045 Lys Lys Lys Lys Pro Ser Arg Leu Lys Gly Asp Asn Glu Lys His Ser 2050 2055 2060 Pro Arg Asn Met Gly Gly He Leu Gly Glu Asp Leu Thr Leu Asp Leu 2065 2070 2075 2080 Lys Asp He Gin Arg Pro Asp Ser Glu His Gly Leu Ser Pro Asp Ser 2085 2090 2095 Glu Asn Phe Asp Trp Lys Ala He Gin Glu Gly Ala Asn Ser He Val 2100 2105 2110 Ser Ser Leu His Gin Ala Ala Ala Ala Ala Cys Leu Ser Arg Gin Ala 2115 2120 2125 Ser Ser Asp Ser Asp Ser He Leu Ser Leu Lys Ser Gly He Ser Leu 2130 2135 2140 Gly Ser Pro Phe His Leu Thr Pro Asp Gin Glu Glu Lys Pro Phe Thr 2145 2150 2155 2160 Ser Asn Lys Gly Pro Arg He Leu Lys Pro Gly Glu Lys Ser Thr Leu 2165 2170 2175 Glu Thr Lys Lys He Glu Ser Glu Ser Lys Gly He Lys Gly Gly Lys 2180 2185 2190 Lys Val Tyr Lys Ser Leu He Thr Gly Lys Val Arg Ser Asn Ser Glu 2195 2200 2205 He Ser Gly Gin Met Lys Gin Pro Leu Gin Ala Asn Met Pro Ser He 2210 2215 2220 Ser Arg Gly Arg Thr Met He His He Pro Gly Val Arg Asn Ser Ser 2225 2230 2235 2240 Ser Ser Thr Ser Pro Val Ser Lys Lys Gly Pro Pro Leu Lys Thr Pro 2245 2250 2255 Ala Ser Lys Ser Pro Ser Glu Gly Gin Thr Ala Thr Thr Ser Pro Arg 2260 2265 2270 Gly Ala Lys Pro Ser Val Lys Ser Glu Leu Ser Pro Val Ala Arg Gin 2275 2280 2285 Thr Ser Gin He Gly Gly Ser Ser Lys Ala Pro Ser Arg Ser Gly Ser 2290 2295 2300 Arg Asp Ser Thr Pro Ser Arg Pro Ala Gin Gin Pro Leu Ser Arg Pro 2305 2310 2315 2320 He Gin Ser Pro Gly Arg Asn Ser He Ser Pro Gly Arg Asn Gly He 2325 2330 2335 Ser Pro Pro Asn Lys He Ser Gin Leu Pro Arg Thr Ser Ser Pro Ser 2340 2345 2350 Thr Ala Ser Thr Lys Ser Ser Gly Ser Gly Lys Met Ser Tyr Thr Ser 2355 2360 2365 Pro Gly Arg Gin Met Ser Gin Gin Asn Leu Thr Lys Gin Thr Gly Leu 2370 2375 2380 Ser Lys Asn Ala Ser Ser He Pro Arg Ser Glu Ser Ala Ser Lys Gly 2385 2390 2395 2400 Leu Asn Gin Met Asn Asn Gly Asn Gly Ala Asn Lys Lys Val Glu Leu 2405 2410 2415 Ser Arg Met Ser Ser Thr Lys Ser Ser Gly Ser Glu Ser Asp Arg Ser 2420 2425 2430 Glu Arg Pro Val Leu Val Arg Gin Ser Thr Phe He Lys Glu Ala Pro 2435 2440 2445 Ser Pro Thr Leu Arg Arg Lys Leu Glu Glu Ser Ala Ser Phe Glu Ser 2450 2455 2460 Leu Ser Pro Ser Ser Arg Pro Ala Ser Pro Thr Arg Ser Gin Ala Gin 2465 2470 2475 2480 Thr Pro Val Leu Ser Pro Ser Leu Pro Asp Met Ser Leu Ser Thr His 2485 2490 2495 Ser Ser Val Gin Ala Gly Gly Trp Arg Lys Leu Pro Pro Asn Leu Ser 2500 2505 2510 Pro Thr He Glu Tyr Asn Asp Gly Arg Pro Ala Lys Arg His Asp He 2515 2520 2525 Ala Arg Ser His Ser Glu Ser Pro Ser Arg Leu Pro He Asn Arg Ser 2530 2535 2540 Gly Thr Trp Lys Arg Glu His Ser Lys His Ser Ser Ser Leu Pro Arg 2545 2550 2555 2560 Val Ser Thr Trp Arg Arg Thr Gly Ser Ser Ser Ser He Leu Ser Ala 2565 2570 2575 Ser Ser Glu Ser Ser Glu Lys Ala Lys Ser Glu Asp Glu Lys His Val 2580 2585 2590 Asn Ser He Ser Gly Thr Lys Gin Ser Lys Glu Asn Gin Val Ser Ala 2595 2600 2605 Lys Gly Thr Trp Arg Lys He Lys Glu Asn Glu Phe Ser Pro Thr Asn 2610 2615 2620 Ser Thr Ser Gin Thr Val Ser Ser Gly Ala Thr Asn Gly Ala Glu Ser 2625 2630 2635 2640 Lys Thr Leu He Tyr Gin Met Ala Pro Ala Val Ser Lys Thr Glu Asp 2645 2650 2655 Val Trp Val Arg He Glu Asp Cys Pro He Asn Asn Pro Arg Ser Gly 2660 2665 2670 Arg Ser Pro Thr Gly Asn Thr Pro Pro Val He Asp Ser Val Ser Glu 2675 2680 2685 Lys Ala Asn Pro Asn He Lys Asp Ser Lys Asp Asn Gin Ala Lys Gin 2690 2695 2700 Asn Val Gly Asn Gly Ser Val Pro Met Arg Thr Val Gly Leu Glu Asn 2705 2710 2715 2720 Arg Leu Asn Ser Phe He Gin Val Asp Ala Pro Asp Gin Lys Gly Thr 2725 2730 2735 Glu He Lys Pro Gly Gin Asn Asn Pro Val Pro Val Ser Glu Thr Asn 2740 2745 2750 Glu Ser Ser He Val Glu Arg Thr Pro Phe Ser Ser Ser Ser Ser Ser 2755 2760 2765 Lys His Ser Ser Pro Ser Gly Thr Val Ala Ala Arg Val Thr Pro Phe 2770 2775 2780 Asn Tyr Asn Pro Ser Pro Arg Lys Ser Ser Ala Asp Ser Thr Ser Ala 2785 2790 2795 2800 Arg Pro Ser Gin He Pro Thr Pro Val Asn Asn Asn Thr Lys Lys Arg 2805 2810 2815 Asp Ser Lys Thr Asp Ser Thr Glu Ser Ser Gly Thr Gin Ser Pro Lys 2820 2825 2830 Arg His Ser Gly Ser Tyr Leu Val Thr Ser Val 2835 2840 (2) INFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 65 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iii) HYPOTHETICAL: NO (iv) ANTI -SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: CGGAATTCNN NNNNNNNAAC AGCNNNNNNN NNAATGAANN NCAAAGTCTG NNNTGAGGAT 60 CCTCA 65 (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 65 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: CGGAATTCGA CTCAGAANNN NNNAACTTCA GANNNNNNAT CNNNNNNNNN GTCTGAGGAT 60 CCTCA 65 (2) INFORMATION FOR SEQ ID NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 65 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33: CGGAATTCNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNTGAGGAT 60 CCTCA 65

Claims: hat is claimed is: 1. A composition capable of inhibiting specific binding between a signal-transducing protein and a cytoplasmic protein containing the amino acid sequence (G/S/A/E) -L-G- (F/I/L) , wherein each represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, and each slash within such parentheses separating the alternative amino acids. 2. The composition of claim 1, wherein the cytoplasmic protein contains the amino acid sequence (K/R/Q) -X n - (G/S/A/E) -L-G- (F/I/L) , wherein X represents any amino acid which is selected from the group comprising the twenty naturally occurring amino acids and n represents at least 2, but not more than 4. 3. The composition of claim 1, wherein the cytoplasmic protein contains the amino acid sequence SLGI . 4. The composition of claim 1, wherein the signal - transducing protein has at its carboxyl terminus the amino acid sequence (S/T) -X- (V/I/L) , wherein each - represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, each slash within such parentheses separating the alternative amino acids, and the X represents any amino acid which is selected from the group comprising the twenty naturally occurring amino acids . 5. The composition of claim 1, wherein the composition comprises an antibody, an inorganic compound, an organic compound, a peptide, a peptidomimetic compound, a polypeptide, or a protein. 6. The composition of claim 5, wherein the peptide comprises the sequence (S/T) -X- (V/I/L) -COOH, wherein each - represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, each slash within such parentheses separating the alternative amino acids, the X represents any amino acid which is selected from the group comprising the twenty naturally occurring amino acids . 7. The composition of claim 6, wherein the peptide has the amino acid sequence DSENSNFRNEIQSLV. 8. The composition of claim 6, wherein the peptide has the amino acid sequence RNEIQSLV. 9. The composition of claim 6, wherein the peptide has the amino acid sequence NEIQSLV. 10. The composition of claim 6, wherein the peptide has the amino acid sequence EIQSLV. 11. The composition of claim 6, wherein the peptide has the amino acid sequence IQSLV. 12. The composition of claim 6, wherein the peptide has the amino acid sequence QSLV. 13. The composition of claim 6, wherein the peptide has the amino acid sequence SLV. 14. The composition of claim 6, wherein the peptide has the amino acid sequence IPPDSEDGNEEQSLV. 15. The composition of claim 6, wherein the peptide has the amino acid sequence DSEMYNFRSQLASW . 16. The composition of claim 6, wherein the peptide has the amino acid sequence IDLASEFLFLSNSFL. 17. The composition of claim 6, wherein the peptide has the amino acid sequence PPTCSQANSGRISTL. 18. The composition of claim 6, wherein the peptide has the amino acid sequence SDSNMNMNELSE . 19. The composition of claim 6, wherein the peptide has the amino acid sequence QNFRTYIVSFV. 20. The composition of claim 6, wherein the peptide has the amino acid sequence RETIESTV. 21. The composition of claim 6, wherein the peptide has the amino acid sequence RGFISSLV. 22. The composition of claim 6, wherein the peptide has the amino acid sequence TIQSVI . 23. The composition of claim 6, wherein the peptide has the amino acid sequence ESLV. 24. The composition of claim 6, wherein the organic compound has the sequence Ac-SLV-COOH, wherein the Ac represents an acetyl, each - represent a peptide bond. 25. A composition capable of inhibiting specific binding between a signal-transducing protein having at its carboxyl terminus the amino acid sequence (S/T) -X- (V/I/L) , wherein each - represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, each slash within such parentheses separating the alternative amino acids, the X represents any amino acid which is selected from the group comprising the twenty naturally occurring amino acids, and a cytoplasmic protein. 26. The composition of claim 25, wherein the composition comprises an antibody, an inorganic compound, an organic compound, a peptide, a peptidomimetic compound, a polypeptide or a protein. 27. A method of identifying a compound capable of inhibiting specific binding between a signal - transducing protein and a cytoplasmic protein containing the amino acid sequence (G/S/A/E) -L-G- (F/I/L) , wherein each - represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, each slash within such parentheses separating the alternative amino acids, which comprises: (a) contacting the cytoplasmic protein bound to the signal -transducing protein with a plurality of compounds under conditions permitting binding between a known compound previously shown to be able to displace the signal -transducing protein bound to the cytoplasmic protein and the bound cytoplasmic protein to form a complex; and (b) detecting the displaced signal -transducing protein or the complex formed in step (a) , wherein the displacement indicates that the compound is capable of inhibiting specific binding between the signal -transducing protein and the cytoplasmic protein. 28. The method of claim 27, wherein the inhibition of specific binding between the signal -transducing protein and the cytoplasmic protein affects the transcription activity of a reporter gene. 29. The method of claim 28, where in step (b) the displaced signal-transducing protein or the complex is detected by comparing the transcription activity of a reporter gene before and after the contacting with the compound in step (a) , where a change of the activity indicates that the specific binding between the signal -transducing protein and the cytoplasmic protein is inhibited and the signal-transducing protein is displaced. 30. The method of claim 27, wherein the cytoplasmic protein is bound to a solid support. 31. The method of claim 27, wherein the compound is bound to a solid support . 32. The method of claim 27, wherein the compound comprises an antibody, an inorganic compound, an organic compound, a peptide, a peptidomimetic compound, a polypeptide or a protein. 33. The method of claim 27, wherein the contacting of step (a) is in vitro. 34. The method of claim 27, wherein the contacting of step (a) is in vivo . 35. The method of claim 34, wherein the contacting of step (a) is in a yeast cell. 36. The method of claim 34, wherein the contacting or step (a) is in a mammalian cell. 37. The method of claim 27, wherein the signal- transducing protein is a cell surface receptor. 38. The method of claim 27, wherein the signal- transducing protein is a signal transducer protein. 39. The method of claim 27, wherein the signal- transducing protein is a tumor suppressor protein. 40. The method of claim 37, wherein the cell surface protein is the Fas receptor. 41. The method of claim 40, wherein the Fas receptor is expressed in cells derived from organs comprising the thymus, liver, kidney, colon, ovary, breast, testis, spleen, stomach, prostate, uterus, skin, head and neck. 42. The method of claim 40, wherein the Fas receptor is expressed in cells comprising T-cells and B-cells. 43. The method of claim 37, wherein the cell-surface receptor is the CD4 receptor. 44. The method of claim 37, wherein the cell-surface receptor is the p75 receptor. 45. The method of claim 37, wherein the cell-surface receptor is the serotonin 2A receptor. 46. The method of claim 37, wherein the cell-surface receptor is the serotonin 2B receptor. 47. The method of claim 38, wherein the signal transducer protein is Protein Kinase-C-α-type . 48. The method of claim 39, wherein the tumor suppressor protein is adenomatosis polyposis coli tumor suppressor protein. 49. The method of claim 39, wherein the tumor suppressor protein protein is the colorectal mutant cancer protein. 50. The method of claim 27, wherein the cytoplasmic protein contains the amino acid sequence SLGI, wherein each - represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, and each slash within such parentheses separating the alternative amino acids . 51. The method of claim 40, wherein the cytoplasmic protein is Fas-associated phosphatase- 1. 52. A method of identifying a compound capable of inhibiting specific binding between a signal- transducing protein having at its carboxyl terminus the amino acid sequence (S/T) -X- (V/I/L) , wherein each - represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, each slash within such parentheses separating the alternative amino acids, the X represents any amino acid which is selected from the group comprising the twenty naturally occurring amino acids, and a cytoplasmic protein, which comprises: (a) contacting the signal -transducing protein bound to the cytoplasmic protein with a plurality of compounds under conditions permitting binding between a known compound previously shown to be able to displace the cytoplasmic protein bound to the signal- transducing protein and the bound signal- transducing protein to form a complex; and (b) detecting the displaced cytoplasmic protein or the complex of step (a) wherein the displacement indicates that the compound is capable of inhibiting specific binding between the signal-transducing protein and the cytoplasmic protein. 53. The method of claim 52, wherein the inhibition of specific binding between the signal- transducing protein and the cytoplasmic protein affects the transcription activity of a reporter gene. 54. The method of claim 53, where in step (b) the displaced cytoplasmic protein or the complex is detected by comparing the transcription activity of a reporter gene before and after the contacting with the compound in step (a) , where a change of the activity indicates that the specific binding between the signal-transducing protein and the cytoplasmic protein is inhibited and the cytoplasmic protein is displaced. 55. The method of claim 52, wherein the cytoplasmic protein is bound to a solid support. 56. The method of claim 52, wherein the compound is bound to a solid support. 57. The method of claim 52, wherein the compound comprises an antibody, an inorganic compound, an organic compound, a peptide, a peptidomimetic compound, a polypeptide or a protein. 58. The method of claim 52, wherein the contacting of step (a) is in vitro. 59. The method of claim 52, wherein the contacting of step (a) is in vivo . 60. The method of claim 59, wherein the contacting of step (a) is in a yeast cell. 61. The method of claim 59, wherein the contacting or step (a) is in a mammalian cell. 62. The method of claim 52, wherein the signal- transducing protein is a cell surface receptor. 63. The method of claim 52, wherein the signal- transducing protein is a signal transducer protein. 64. The method of claim 52, wherein the signal- transducing protein is a tumor suppressor protein. 65. The method of claim 62, wherein the cell surface protein is the Fas receptor. 66. The method of claim 65, wherein the Fas receptor is expressed in cells derived from organs comprising the thymus, liver, kidney, colon, ovary, breast, testis, spleen, stomach, prostate, uterus, skin, head and neck. 67. The method of claim 65, wherein the Fas receptor is expressed in cells comprising T-cells and B-cells. 68. The method of claim 62, wherein the cell-surface receptor is the CD4 receptor. 69. The method of claim 62, wherein the cell-surface receptor is the p75 receptor. 70. The method of claim 62, wherein the cell-surface receptor is the serotonin 2A receptor. 71. The method of claim 62, wherein the cell-surface receptor is the serotonin 2B receptor. 72. The method of claim 63, wherein the signal transducer protein is Protein Kinase-C-α-type . 73. The method of claim 64, wherein the tumor suppressor protein is adenomatosis polyposis coli tumor suppressor protein. 74. The method of claim 6 , wherein the tumor suppressor protein is the colorectal mutant cancer protein. 75. The method of claim 52, wherein the cytoplasmic protein contains the amino acid sequence SLGI, wherein each - represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, and each slash within such parentheses separating the alternative amino acids . 76. The method of claim 52, wherein the cytoplasmic protein is Fas-associated phosphatase-1. 77. A method inhibiting the proliferation of cancer cells comprising the composition of claim 1. 78. The method of claim 77, wherein the cancer cells are derived from organs comprising the thym s, liver, kidney, colon, ovary, breast, testis, spleen, stomach, prostate, uterus, skin, head and neck. 79. The method of claim 77, wherein the cancer cells are derived from cells comprising T-cells and B-cells. 80. A method of inhibiting the proliferation of cancer cells comprising the composition of claim 25. 81. The method of claim 80, wherein the cancer cells are derived from organs comprising the thymus, liver, kidney, colon, ovary, breast, testis, spleen, stomach, prostate, uterus, skin, head and neck. 82. The method of claim 80, wherein the cancer cells are derived from cells comprising T-cells and B-cells. 83. A method of inhibiting the proliferation of cancer cells comprising the compound identified by the method of claim 27. 84. The method of claim 83, wherein the cancer cells are derived from organs comprising the thymus, liver, kidney, colon, ovary, breast, testis, spleen, stomach, prostate, uterus, skin, head and neck. 85. The method of claim 83, wherein the cancer cells are derived from cells comprising T-cells and B-cells. 86. A method of inhibiting the proliferation of cancer cells comprising the compound identified by the method of claim 52. 87. The method of claim 86, wherein the cancer cells are derived from organs comprising the thymus, liver, kidney, colon, ovary, breast, testis, spleen, stomach, prostate, uterus, skin, head and neck. 88. The method of claim 86, wherein the cancer cells are derived from cells comprising T-cells and B-cells. 89. A method of treating cancer in a subject which comprises introducing to the subject's cancerous cells an amount of the composition of claim 1 effective to result in apoptosis of the cells. 90. The method of claim 89, wherein the cancer cells are derived from organs comprising the thymus, liver, kidney, colon, ovary, breast, testis, spleen, stomach, prostate, uterus, skin, head and neck. 91. The method of claim 89, wherein the cancer cells are derived from cells comprising T-cells and B-cells. 92. A method of treating cancer in a subject which comprises introducing to the subject's cancerous cells an amount of the composition of claim 25 effective to result in apoptosis of the cells. 93. The method of claim 92, wherein the cancer cells are derived from organs comprising the thymus, liver, kidney, colon, ovary, breast, testis, spleen, stomach, prostate, uterus, skin, head and neck. 94. The method of claim 92, wherein the cancer cells are derived from cells comprising T-cells and B-cells. 95. A method of treating cancer in a subject which comprises introducing to the subject's cancerous cells an amount of the compound identified by the method of claim 27 effective to allow apoptosis of the cells . 96. The method of claim 95, wherein the cancer cells are derived from organs comprising the thymus, liver, kidney, colon, ovary, breast, testis, spleen, stomach, prostate, uterus, skin, head and neck. 97. The method of claim 95, wherein the cancer cells are derived from cells comprising T-cells and B-cells. 98. A method of treating cancer in a subject which comprises introducing to the subject's cancerous cells an amount of the compound identified by the method of claim 52 effective to result in apoptosis of the cells. 99. The method of claim 98, wherein the cancer cells are derived from organs comprising the thymus, liver, kidney, colon, ovary, breast, testis, spleen, stomach, prostate, uterus, skin, head and neck. 100. The method of claim 98, wherein the cancer cells are derived from cells comprising T-cells and B-cells. 101. A method of inhibiting the proliferation of virally infected cells comprising the composition of claim 1. 102. A method of inhibiting the proliferation of virally infected cells comprising the composition of claim 25. 103. A method of inhibiting the proliferation of virally infected cells comprising the compound identified by the method of claim 27. 104. A method of inhibiting the proliferation of virally infected cells comprising the compound identified by the method of claim 52. 105. The method of claim 101, wherein the virally infected cells comprise Hepatitis B virus, Epstein- Barr virus, influenza virus, Papilloma virus. Adeno virus, Human T-cell lymphtropic virus, type 1 or HIV. 106. The method of claim 102, wherein the virally infected cells comprise Hepatitis B virus, Epstein- Barr virus, influenza virus, Papilloma virus. Adeno virus, Human T-cell lymphtropic virus, type 1 or HIV. 107. The method of claim 103, wherein the virally infected cells comprise Hepatitis B virus, Epstein- Barr virus, influenza virus, Papilloma virus. Adeno virus, Human T-cell lymphtropic virus, type 1 or HIV. 108. The method of claim 104, wherein the virally infected cells comprise Hepatitis B virus, Epstein- Barr virus, influenza virus, Papilloma virus. Adeno virus, Human T-cell lymphtropic virus, type 1 or HIV. 109. A method of treating a virally-infected subject which comprises introducing to the subject's virally- infected cells the composition of claim 1 effective to result in apoptosis of the cells. 110. A method of treating a virally-infected subject which comprises introducing to the subject's virally infected cells the composition of claim 25 effective to result in apoptosis of the cells. 111. A method of treating a virally-infected subject which comprises introducing to the subject's virally-infected cells an amount of the compound identified by the method of claim 27 effective to result in apoptosis of the cells. 112. A method of treating a virally-infected subject which comprises introducing to the subject's virally- infected cells an amount of the compound identified by the method of claim 52 effective to result in apoptosis of the cells. 113. The method of claim 109, wherein the virally infected cells comprise the Hepatitis B virus, Epstein-Barr virus, influenza virus, Papilloma virus. Adeno virus, Human T-cell lymphtropic virus, type 1 or HIV. 114. The method of claim 110, wherein the virally infected cells comprise the Hepatitis B virus, Epstein-Barr virus, influenza virus, Papilloma virus. Adeno virus, Human T-cell lymphtropic virus, type 1 or HIV. 115. The method of claim 111, wherein the virally infected cells comprise the Hepatitis B virus, Epstein-Barr virus, influenza virus, Papilloma virus. Adeno virus, Human T-cell lymphtropic virus, type 1 or HIV. 116. The method of claim 112, wherein the virally infected cells comprise the Hepatitis B virus, Epstein-Barr virus, influenza virus, Papilloma virus. Adeno virus, Human T-cell lymphtropic virus, type 1 or HIV. 117. A pharmaceutical composition comprising the composition of claim 1 in an effective amount and a pharmaceutically acceptable carrier. 118. A pharmaceutical composition comprising the composition of claim 25 in an effective amount and a pharmaceutically acceptable carrier. 119. A pharmaceutical composition comprising the compound identified by the method of claim 27 in an effective amount and a pharmaceutically acceptable carrier. A pharmaceutical composition comprising the compound identified by the method of claim 52 in an effective amount and a pharmaceutically acceptable carrier.

Inventors: SATO TAKA-AKI, YANAGISAWA JUNN, SATO, TAKA-AKI, YANAGISAWA, JUNN
Applicants: SATO TAKA AKI, UNIV COLUMBIA, YANAGISAWA JUNN, SATO, TAKA-AKI, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF, YANAGISAWA, JUNN
Application year: 1997
Main classification: A61K38
IPC codes: A61K38, A61K45, A61P31, A61P35, A61P43, C07K5, C07K7, C07K14, G01N33